Inari Medical (NARI) 10-Q 11 Aug 20 2020 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2020	Aug. 07, 2020
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2020
Document Transition Report	false
Document Fiscal Year Focus	2020
Entity File Number	001-39293
Entity Registrant Name	Inari Medical, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	45-2902923
Entity Address, Address Line One	9 Parker
Entity Address, Address Line Two	Suite 100
Entity Address, City or Town	Irvine
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92618
City Area Code	877
Local Phone Number	923-4747
Title of 12(b) Security	Common stock, $0.001 par value per share
Trading Symbol	NARI
Security Exchange Name	NASDAQ
Entity Current Reporting Status	No
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		48,522,958
Entity Central Index Key	0001531048
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q2
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Current assets
Cash and cash equivalents	$ 194,836	$ 23,639
Restricted cash	50	50
Accounts receivable, net	15,392	11,302
Inventories, net	5,620	3,953
Prepaid expenses and other current assets	3,866	464
Total current assets	219,764	39,408
Property and equipment, net	4,176	3,331
Restricted cash	338	338
Deposits and other assets	76	1,469
Total assets	224,354	44,546
Current liabilities
Accounts payable	2,294	2,549
Payroll-related accruals	7,223	5,225
Accrued expenses and other current liabilities	1,385	1,096
Total current liabilities	10,902	8,870
Notes payable, net	29,582	19,481
Warrant liabilities		1,169
Total liabilities	40,484	29,520
Commitments and contingencies (Note 6)
Mezzanine equity
Redeemable convertible preferred stock, par value $0.001, no shares authorized, issued, and outstanding as of June 30, 2020; 32,225,227 shares authorized, 31,968,570 shares issued and outstanding as of December 31, 2019; aggregate liquidation preference of zero as of June 30, 2020 and $54,415 as of December 31, 2019		54,170
Stockholders' equity (deficit)
Preferred stock, $0.001 par value, 10,000,000 shares authorized, no shares issued and outstanding at June 30, 2020; no shares authorized, issued, and outstanding at December 31, 2019
Common stock, $0.001 par value, 300,000,000 and 49,019,607 shares authorized as of June 30, 2020 and December 31, 2019, respectively; 48,360,081 and 6,720,767 shares issued and outstanding as of June 30, 2020 and December 31, 2019, respectively	48	7
Additional paid in capital	224,726	2,061
Accumulated deficit	(40,904)	(41,212)
Total stockholders' equity (deficit)	183,870	(39,144)
Total liabilities, mezzanine equity and stockholders' equity (deficit)	$ 224,354	$ 44,546

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Statement Of Financial Position [Abstract]
Redeemable convertible preferred stock, par value	$ 0.001	$ 0.001
Redeemable convertible preferred stock, shares authorized		32,225,227
Redeemable convertible preferred stock, shares issued		31,968,570
Redeemable convertible preferred stock, shares outstanding	0	31,968,570
Redeemable convertible preferred stock, liquidation preference	$ 0	$ 54,415
Preferred stock, Par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	300,000,000	49,019,607
Common stock, shares issued	48,360,081	6,720,767
Common stock, shares outstanding	48,360,081	6,720,767

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Income Statement [Abstract]
Revenue	$ 25,392	$ 10,072	$ 52,345	$ 17,017
Cost of goods sold	3,487	1,331	6,193	2,262
Gross profit	21,905	8,741	46,152	14,755
Operating expenses
Research and development	3,628	1,580	6,646	2,789
Selling, general and administrative	18,880	7,803	35,273	13,229
Total operating expenses	22,508	9,383	41,919	16,018
Income (loss) from operations	(603)	(642)	4,233	(1,263)
Other income (expense)
Interest income	146	24	201	48
Interest expense	(463)	(229)	(809)	(456)
Change in fair value of warrant liabilities	(2,884)	(118)	(3,317)	(242)
Total other expenses	(3,201)	(323)	(3,925)	(650)
Net income (loss) and comprehensive income (loss)	$ (3,804)	$ (965)	$ 308	$ (1,913)
Net income (loss) per share
Basic	$ (0.16)	$ (0.17)	$ 0.02	$ (0.34)
Diluted	$ (0.16)	$ (0.17)	$ 0.01	$ (0.34)
Weighted average common shares used to compute net income (loss) per share,
Basic	24,295,900	5,753,332	15,339,755	5,676,995
Diluted	24,295,900	5,753,332	47,362,292	5,676,995

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Mezzanine Equity and Stockholders' Equity (Deficit) (Unaudited) - USD ($) $ in Thousands	Total	Common Stock	Subscription Receivable	Additional Paid In Capital	Accumulated Deficit	Cumulative Effect, Period of Adoption, Adjustment	Cumulative Effect, Period of Adoption, AdjustmentAccumulated Deficit	Redeemable Convertible Preferred Stock
Beginning Balance at Dec. 31, 2018								$ 54,170
Beginning Balance, Shares at Dec. 31, 2018								31,968,570
Beginning Balance at Dec. 31, 2018	$ (39,446)	$ 6	$ (758)	$ 1,430	$ (40,124)	$ 104	$ 104
Beginning Balance, Shares at Dec. 31, 2018		6,310,865
Options exercised for common stock	11			11
Options exercised for common stock, Shares		50,806
Interest earned on subscription receivable	(4)		(4)
Share based compensation expense	91			91
Net income	(948)				(948)
Ending Balance at Mar. 31, 2019								$ 54,170
Ending Balance, Shares at Mar. 31, 2019								31,968,570
Ending Balance at Mar. 31, 2019	(40,192)	$ 6	(762)	1,532	(40,968)
Ending Balance, Shares at Mar. 31, 2019		6,361,671
Beginning Balance at Dec. 31, 2018								$ 54,170
Beginning Balance, Shares at Dec. 31, 2018								31,968,570
Beginning Balance at Dec. 31, 2018	(39,446)	$ 6	(758)	1,430	(40,124)	$ 104	$ 104
Beginning Balance, Shares at Dec. 31, 2018		6,310,865
Net income	(1,913)
Ending Balance at Jun. 30, 2019								$ 54,170
Ending Balance, Shares at Jun. 30, 2019								31,968,570
Ending Balance at Jun. 30, 2019	(41,053)	$ 6	(766)	1,640	(41,933)
Ending Balance, Shares at Jun. 30, 2019		6,392,844
Beginning Balance at Mar. 31, 2019								$ 54,170
Beginning Balance, Shares at Mar. 31, 2019								31,968,570
Beginning Balance at Mar. 31, 2019	(40,192)	$ 6	(762)	1,532	(40,968)
Beginning Balance, Shares at Mar. 31, 2019		6,361,671
Options exercised for common stock	9			9
Options exercised for common stock, Shares		31,173
Interest earned on subscription receivable	(4)		(4)
Share based compensation expense	99			99
Net income	(965)				(965)
Ending Balance at Jun. 30, 2019								$ 54,170
Ending Balance, Shares at Jun. 30, 2019								31,968,570
Ending Balance at Jun. 30, 2019	(41,053)	$ 6	$ (766)	1,640	(41,933)
Ending Balance, Shares at Jun. 30, 2019		6,392,844
Beginning Balance at Dec. 31, 2019	$ 54,170							$ 54,170
Beginning Balance, Shares at Dec. 31, 2019	31,968,570							31,968,570
Beginning Balance at Dec. 31, 2019	$ (39,144)	$ 7		2,061	(41,212)
Beginning Balance, Shares at Dec. 31, 2019		6,720,767
Options exercised for common stock	22			22
Options exercised for common stock, Shares		58,498
Share based compensation expense	495			495
Net income	4,112				4,112
Ending Balance at Mar. 31, 2020								$ 54,170
Ending Balance, Shares at Mar. 31, 2020								31,968,570
Ending Balance at Mar. 31, 2020	(34,515)	$ 7		2,578	(37,100)
Ending Balance, Shares at Mar. 31, 2020		6,779,265
Beginning Balance at Dec. 31, 2019	$ 54,170							$ 54,170
Beginning Balance, Shares at Dec. 31, 2019	31,968,570							31,968,570
Beginning Balance at Dec. 31, 2019	$ (39,144)	$ 7		2,061	(41,212)
Beginning Balance, Shares at Dec. 31, 2019		6,720,767
Net income	$ 308
Ending Balance, Shares at Jun. 30, 2020	0
Ending Balance at Jun. 30, 2020	$ 183,870	$ 48		224,726	(40,904)
Ending Balance, Shares at Jun. 30, 2020		48,360,081
Beginning Balance at Mar. 31, 2020								$ 54,170
Beginning Balance, Shares at Mar. 31, 2020								31,968,570
Beginning Balance at Mar. 31, 2020	(34,515)	$ 7		2,578	(37,100)
Beginning Balance, Shares at Mar. 31, 2020		6,779,265
Conversion of preferred stock to common stock upon initial public offering								$ (54,170)
Conversion of preferred stock to common stock upon initial public offering, Shares								(31,968,570)
Conversion of preferred stock to common stock upon initial public offering	54,170	$ 32		54,138
Conversion of preferred stock to common stock upon initial public offering, Shares		31,968,570
Issuance of common stock in connection with initial public offering, net of issuance costs of $16.3 million	162,979	$ 9		162,970
Issuance of common stock in connection with initial public offering, net of issuance costs of $16.3 million, Shares		9,432,949
Conversion and reclassification of preferred stock warrants to common stock warrants upon initial public offering	4,486			4,486
Exercise of common stock warrants	4			4
Exercise of common stock warrants, Shares		102,533
Options exercised for common stock	45			45
Options exercised for common stock, Shares		76,764
Share based compensation expense	505			505
Net income	$ (3,804)				(3,804)
Ending Balance, Shares at Jun. 30, 2020	0
Ending Balance at Jun. 30, 2020	$ 183,870	$ 48		$ 224,726	$ (40,904)
Ending Balance, Shares at Jun. 30, 2020		48,360,081

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Mezzanine Equity and Stockholders' Equity (Deficit) (Unaudited) (Parenthetical) $ in Millions	6 Months Ended
	Jun. 30, 2020USD ($)
Statement Of Stockholders Equity [Abstract]
Stock issuance cost	$ 16.3

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Cash flows from operating activities
Net income (loss)	$ 308	$ (1,913)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation	573	228
Amortization of deferred financing costs	113	46
Share based compensation expense	1,000	190
Amortization of fair value of warrants issued with debt		8
Provision for doubtful accounts	84
Loss on change in fair value of warrant liabilities	3,317	242
Changes in:
Accounts receivable	(4,174)	(3,572)
Inventories	(1,667)	(1,082)
Prepaid expenses and other assets	(3,391)	17
Accounts payable	(255)	147
Payroll-related accruals, accrued liabilities and other liabilities	2,287	1,914
Net cash used in operating activities	(1,805)	(3,775)
Cash flows from investing activities
Purchase of property and equipment	(1,418)	(899)
Net cash used in investing activities	(1,418)	(899)
Cash flows from financing activities
Proceeds from issuance of common stock upon initial public offering, net of issuance costs paid	164,361
Proceeds from notes payable	10,000
Debt financing costs	(12)
Proceeds from exercise of stock options	67	20
Proceeds from warrants exercises	4
Net cash provided by financing activities	174,420	20
Net increase (decrease) in cash	171,197	(4,654)
Cash, cash equivalents and restricted cash beginning of period	24,027	21,884
Cash, cash equivalents and restricted cash end of period	195,224	17,230
Supplemental disclosures of cash flow information:
Cash paid for income taxes	81	10
Cash paid for interest	618	$ 403
Noncash investing and financing:
Common stock issued on conversion of convertible preferred stock	54,170
Common stock warrants issued on conversion of preferred stock warrants and the reclassification of the warrant liability	4,486
Deferred initial public offering cost recorded to additional paid in capital	1,382
Accrual of deferred interest obligation associated with debt	$ 100

Organization

Organization	6 Months Ended
	Jun. 30, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Organization	1. Organization Inari Medical, Inc. (the “Company”) was incorporated in Delaware in July 2011 and is headquartered in Irvine, California. The Company develops, manufactures, markets and sells devices for the interventional treatment of venous diseases. The Company received initial 510(k) clearance from the U.S. Food and Drug Administration (the “FDA”) in February 2015 for its FlowTriever system, used primarily to treat pulmonary emboli, and in February 2017 for its ClotTriever system, used for the treatment of deep vein thrombosis. Initial Public Offering In May 2020, the Company completed an initial public offering (“IPO”) of its common stock. As part of the IPO, the Company issued and sold 9,432,949 shares of its common stock, which included 1,230,384 shares sold pursuant to the exercise of the underwriters’ over-allotment option, at a public offering price of $19.00 per share. The Company received net proceeds of approximately $163.0 million from the IPO, after deducting underwriters’ discounts and commissions of $12.6 million and offering costs of $3.7 million, of which $1.4 million was incurred as of December 31, 2019. Upon the completion of the IPO, all shares of Series A, B, and C redeemable convertible preferred stock then outstanding were converted into 31,968,570 shares of common stock on a one-to-one basis. In addition, on the completion of the IPO, all the Company’s outstanding preferred stock warrants were converted into warrants to purchase an aggregate of 256,588 shares of common stock, which resulted in the reclassification of the convertible preferred stock warrant liability to additional paid-in capital. In connection with the Company’s IPO, in May 2020, the Company’s certificate of incorporation was amended and restated to provide for 300,000,000 authorized shares of common stock with a par value of $0.001 per share and 10,000,000 authorized shares of preferred stock with a par value of $0.001 per share. Reverse Stock Splits In March 2020, the Company’s board of directors approved an amendment to the Company’s certificate of incorporation to effect a reverse split of shares of the Company’s common stock and redeemable convertible preferred stock on a 1-for-1.19 basis. In May 2020, the Company’s board of directors approved an amendment to the Company’s certificate of incorporation to effect a second reverse split of shares of the Company’s common stock and redeemable convertible preferred stock on a 1-for-1.20 basis. All common stock, redeemable convertible preferred stock, warrants, stock options, RSUs and per share information presented in the financial statements have been adjusted to reflect the effect of both reverse stock splits on a retroactive basis for all periods presented. Any fractional shares resulting from the reverse stock splits are rounded down to a whole share.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies COVID-19 and CARES Act The Company has been actively monitoring the novel coronavirus, or COVID-19, situation and its impact. In response to the pandemic, numerous state and local jurisdictions have imposed “shelter-in-place” orders, quarantines and other restrictions. In the United States, governmental authorities have recommended, and in certain cases required, that elective, specialty and other procedures and appointments, be suspended or canceled. Similarly, in March 2020, the governor of California, where the Company’s headquarters are located, issued “stay at home” orders limiting non-essential activities, travel and business operations. Such orders or restrictions have resulted in reduced operations at the Company’s headquarters, work stoppages, slowdowns and delays, travel restrictions and cancellation of events. These orders and restrictions have significantly decreased the number of procedures performed using the Company’s products and otherwise negatively impacted operations. In response to the impact of COVID-19, the Company implemented a variety of measures intended to help manage through the impact and position it to resume operations quickly and efficiently once these restrictions are lifted. Some of these measures include: adapting, expanding and improving various sales, physician outreach and training programs to address the current environment; producing approximately four months’ worth of inventory before temporarily suspending production and executing a work from home strategy for administrative functions. The impact of COVID-19 is changing daily and cannot be predicted. As a result, the Company expects the pandemic to continue to negatively impact its business, financial condition and results of operations. On March 27, 2020, the President signed into law the “Coronavirus Aid, Relief, and Economic Security (CARES) Act.” The CARES Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations, increased limitations on qualified charitable contributions, and technical corrections to tax depreciation methods for qualified improvement property. The Company currently may be eligible but has not taken advantage of the payroll protection program, emergency grants and business loans under the CARES Act. The Company expects to monitor the impact that the CARES Act may have on its business, financial condition, results of operations, or liquidity. Basis of Presentation of Unaudited Interim Condensed Consolidated Financial Statements The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Certain prior year reported amounts have been reclassified to conform with the 2020 presentation. The interim condensed consolidated balance sheet as of June 30, 2020, the condensed consolidated statements of operations, m ezzanine equity and stockholders’ deficit, filed pursuant to Rule 424(b)(4) with the U.S. Securities and Exchange Commission on May 26, 2020 Principles of Consolidation In May 2020, the Company formed Inari Medical International, Inc., a wholly-owned subsidiary incorporated in Delaware. All intercompany balances and transactions have been eliminated in consolidation. Management Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant estimates and assumptions made in the accompanying financial statements include, but are not limited to the collectability of receivables, valuation of inventory, the fair value of common stock warrants, the fair value of preferred stock warrant liabilities, the fair value of stock options, recoverability of the Company’s net deferred tax assets, and related valuation allowance and certain accruals. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates. JOBS Act Accounting Election As an emerging growth company under the Jumpstart Our Business Startups Act of 2012 ("the JOBS Act"), the Company is eligible to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies. the Company has elected to take advantage of the extended transition period for adopting new or revised accounting standards that have different effective dates for public and private companies until such time as those standards apply to private companies. Cash, Cash Equivalents and Restricted Cash The Company considers cash on hand, cash in demand deposit accounts including money market funds, and instruments with a maturity date of 90 days or less at date of purchase to be cash and cash equivalents. The Company maintains its cash, cash equivalent and restricted cash balances with banks. Under the Dodd-Frank Wall Street Reform and Consumer Protection Act, deposits of up to $250,000 at FDIC-insured institutions are covered by FDIC insurance. At times, deposits may be in excess of the FDIC insurance limit; however, management does not believe the Company is exposed to any significant related credit risk. Restricted cash as of June 30, 2020 and December 31, 2019 consisted of a cash secured letter of credit in the amount of $338,000 representing collateral for the Company’s facility lease. Restricted cash additionally included as of June 30, 2020 and December 31, 2019, a compensating balance of $50,000 to secure the Company’s corporate purchasing cards. Accounts Receivable, net Trade accounts receivable are recorded at the invoiced amount, net of any allowance for doubtful accounts. Any allowance for doubtful accounts is developed based upon several factors including the customers’ credit quality, historical write-off experience and any known specific issues or disputes which exist as of the balance sheet date. Account receivable balances are written off against the allowance after appropriate collection efforts are exhausted. The allowance for doubtful accounts was $146,000 and $62,000 as of June 30, 2020 and December 31, 2019, respectively, and no accounts receivable write offs were recognized during the three and six months ended June 30, 2020 and 2019. Despite the Company’s efforts to minimize credit risk exposure, customers could be adversely affected if future economic and industry trends, including those related to COVID-19, change in such a manner as to negatively impact their cash flows. The full effects of COVID-19 on the Company’s customers are highly uncertain and cannot be predicted. As a result, the Company’s future collection experience can differ significantly from historical collection trends. If the Company’s clients experience a negative impact on their cash flows, it could have a material adverse effect on the Company’s results of operations and financial condition. Inventories, net The Company values inventory at the lower of the actual cost to purchase or manufacture the inventory or net realizable value for such inventory. Cost, which includes material, labor and overhead costs, is determined on the first-in, first out method, or FIFO. The Company regularly reviews inventory quantities in process and on hand, and when appropriate, records a provision for obsolete and excess inventory. The Company writes down inventory that has become obsolete, inventory that has a cost basis in excess of its expected net realizable value and inventory in excess of expected requirements based on future demand and as compared to remaining shelf life. The estimate of excess quantities is subjective and primarily dependent on the Company’s estimates of future demand for a particular product. If the estimate of future demand is inaccurate based on actual sales, the Company may increase the write down for excess inventory for that component and record a charge to inventory impairment in the accompanying condensed consolidated statement of operations and comprehensive income (loss). Property and Equipment Property and equipment are stated at cost. Additions and improvements that extend the lives of the assets are capitalized while expenditures for repairs and maintenance are expensed as incurred. Depreciation is provided using the straight-line method over the estimated useful lives of the assets, ranging from three to seven years. Leasehold improvements are depreciated over the shorter of the useful life of the improvement or the lease term, including renewal periods that are reasonably assured. Upon sale or disposition of property and equipment, any gain or loss is included in the accompanying statement of operations. Deferred Initial Public Offering Costs Specific incremental legal, accounting and other fees and costs directly attributable to a proposed or actual offering of securities may properly be deferred and charged against the gross proceeds of the offering. As of December 31, 2019, there were approximately $1,382,000 of offering costs, primarily consisting of legal, accounting and printing fees, which were capitalized in other non-current assets on the balance sheet. In May 2020, upon the closing of the IPO, total deferred costs of approximately $3,701,000 were offset against the Company’s IPO proceeds. Impairment of Long-lived Assets The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparing the carrying amount to the future net undiscounted cash flows which the assets are expected to generate. If such assets are considered impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows arising from the asset. The Company has not identified any such impairment losses to date. Fair Value of Financial Instruments The Company’s cash, cash equivalents and restricted cash, accounts receivable, accounts payable and accrued liabilities approximate their fair value due to their liquidity or short maturities. Management believes that its long term debt bears interest at the prevailing market rates for instruments with similar characteristics; accordingly, the carrying value of this instrument approximates its fair value as of June 30, 2020 and December 31, 2019. The Company measures and records certain financial assets and liabilities at fair value on a recurring basis. U.S. GAAP provides a fair value hierarchy that distinguishes between (i) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (ii) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels. • Level 1—Quoted prices in active markets for identical assets or liabilities. • Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. • Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of assets or liabilities. See Note 3 for further information. Convertible Preferred Stock Warrant Liability The Company has accounted for its freestanding warrants to purchase shares of the Company’s convertible preferred stock as liabilities at fair value upon issuance primarily because the preferred shares underlying the warrants contain contingent redemption features outside the control of the Company. The warrants are subject to remeasurement at each balance sheet date and any change in fair value is recognized as the change in fair value of warrant liability and recorded to other expense in the statements of operations. The carrying value of the warrants continued to be adjusted until the completion of the IPO, which occurred in May 2020. At that time, the preferred stock warrant liability was adjusted to fair value and reclassified to additional paid-in capital, a component of stockholders’ equity (deficit) (see Note 3). Revenue Recognition On January 1, 2019, the Company adopted Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers, Under ASC 606, revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. Product sales of the FlowTriever and ClotTriever systems are made to hospitals in the United States utilizing the Company’s direct sales force. Revenue is comprised of product revenue net of returns, administration fees and sales rebates. Performance Obligation —The Company has revenue arrangements that consist of a single performance obligation, delivery of the Company’s products. The satisfaction of this performance obligation occurs with the transfer of control of the Company’s product to its customers, either upon shipment or delivery of the product. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring goods. The amount of revenue that is recognized is based on the transaction price, which represents the invoiced amount and includes estimates of variable consideration such as rebate and administrative fees, where applicable. The Company provides a 30-day unconditional right of return period. The Company establishes estimated provisions for returns at the time of sale based on historical experience. Historically, the actual product returns have been immaterial to the Company’s financial statements. Assuming all other revenue recognition criteria have been met, the Company recognizes revenue for arrangements where the Company has satisfied its performance obligation of delivering the product. For sales where the Company’s sales representatives hand deliver products directly to the hospital, control of the products transfers to the customer upon such hand delivery. For sales where products are shipped, control of the products transfers either upon shipment or delivery of the products to the customer, depending on the shipping terms and conditions. As of June 30, 2020 and December 31, 2019, the Company recorded $302,000 and $330,000, respectively, of unbilled receivables, which are included in accounts receivable, net, in the accompanying balance sheet. For both the three months ended June 30, 2020 and 2019, 40% of revenue was derived from the sale of ClotTriever products, and 60% of revenue was derived from the sale of FlowTriever products. For the six months ended June 30, 2020 and 2019, 38% and 39% of revenue was derived from the sale of ClotTriever products, respectively, and 62% and 61% of revenue was derived from the sale of FlowTriever products, respectively. The Company offers payment terms to its customer of less than three months and these terms do not include a significant financing component. The Company excludes taxes assessed by governmental authorities on revenue-producing transactions from the measurement of the transaction price. The Company offers its standard warranty to all customers and no warranties are available for sale on a standalone basis. The Company’s warranty provides that its products are free of material defects and conform to specifications, and offer to repair, replace or refund the purchase price of defective products. This assurance does not constitute a service and is not considered a separate performance obligation. The Company estimates warranty liabilities at the time of revenue recognition and records it as a charge to cost of goods sold. Costs associated with product sales include commissions and are recorded in selling, general and administrative expenses. The Company applies the practical expedient and recognizes commissions as expense when incurred because the amortization period is less than one year. Cost of Goods Sold Cost of goods sold consists primarily of the cost of raw materials, components, direct labor and manufacturing overhead. Overhead costs include the cost of quality assurance, material procurement, inventory control, facilities, equipment and operations supervision and management, including stock-based compensation. Cost of goods sold also includes depreciation expense for production equipment and certain direct costs such as shipping costs and royalty expense. Shipping Costs Shipping costs billed to customers are not included in revenue, and are reported as a reduction of costs of goods sold. Advertising Costs Advertising costs are charged to operations as incurred. Advertising costs were $74,000 and $6,000 for the three months ended June 30, 2020 and 2019, respectively and $111,000 and $34,000 for the six months ended June 30, 2020 and 2019, respectively. Advertising costs are included in selling, general and administrative expenses in the accompanying statements of operations. Research and Development Research and development costs are expensed as incurred and include the costs to design, develop, test, deploy and enhance new and existing products. Research and development costs also include expenses associated with clinical studies, registries and sponsored research. These costs include direct salary and employee benefit related costs for research and development personnel, costs for materials used and costs for outside services. Patent-related Expenditures Expenditures related to patent research and applications, which are primarily legal fees, are expensed as incurred and are included in selling, general and administrative expenses in the accompanying statements of operations. Stock-based Compensation The Company’s employee and non-employee share-based awards result in a cost that is measured at fair value on the awards’ grant date, based on the estimated number of awards that are expected to vest. Stock-based compensation is recognized over the service period. Income Taxes The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Management assesses the likelihood that the resulting deferred tax assets will be realized. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. Due to the Company’s historical operating performance and the recorded cumulative net losses in prior fiscal periods, the net deferred tax assets have been fully offset by a valuation allowance. The Company recognizes uncertain income tax positions at the largest amount that is more likely than not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. Changes in recognition or measurement are reflected in the period in which judgment occurs. The Company’s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of provision for income taxes. Foreign Currency Transactions Certain vendors are paid in currencies other than the US dollar. Transaction gains and losses are included in selling, general and administrative expenses. Comprehensive Income (Loss) The Company’s net income (loss) equaled comprehensive income (loss) for the three and six months ended June 30, 2020 and 2019. Net Income (Loss) per Share of Common Stock Basic net income (loss) per share is computed by dividing the net income (loss) attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period, without consideration for potential dilutive common shares. Diluted net income (loss) per share is computed by dividing the net income (loss) attributable to common stockholders by the weighted average number of shares of common stock and potentially dilutive securities outstanding for the period. For purposes of the diluted net income (loss) per share calculation, redeemable convertible preferred stock and warrants, and common stock options are considered to be potentially dilutive securities. For the periods the Company is in a net loss position, basic net loss per share is the same as diluted net loss per share as the inclusion of all potential dilutive common shares would have been anti-dilutive. The Company allocates no loss to participating securities because they have no contractual obligation to share in the losses of the Company. The shares of the Company’s convertible preferred stock participate in any dividends declared by the Company and are therefore considered to be participating securities. Segment Reporting Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (“CODM”) in deciding how to allocate resources to an individual segment and in assessing performance. The Company’s CODM is its Chief Executive Officer. The Company has determined it operates in one segment - the development and commercialization of innovative and minimally invasive mechanical thrombectomy devices to treat thromboembolism in the venous system. Geographically, we sell to hospitals in the United States. Segment information is consistent with how management reviews the business, makes investing and resource allocation decisions and assesses operating performance. Recently Adopted Accounting Pronouncements In June 2018, the FASB issued ASU No. 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting Recent Accounting Pronouncements In February 2017, the FASB issued ASU 2017-02, Leases In June 2016, the FASB issued ASU 2016-13 “ Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2020
Fair Value Disclosures [Abstract]
Fair Value Measurements	3. Fair Value Measurements The following tables summarize the Company’s financial assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy as of June 30, 2020 and December 31, 2019 (in thousands): December 31, 2019 Level 1 Level 2 Level 3 Total Liabilities: Convertible preferred stock warrant liability $ — $ — $ 1,169 $ 1,169 Total liabilities $ — $ — $ 1,169 $ 1,169 June 30, 2020 Level 1 Level 2 Level 3 Total Liabilities: Convertible preferred stock warrant liability $ — $ — $ — $ - Total liabilities $ — $ — $ - $ - The change in the fair value of the warrant liability is summarized below (in thousands): Six Months Ended June 30, 2020 2019 Beginning balance $ 1,169 $ 213 Change in fair value of warrant liability 3,317 242 Conversion of preferred stock warrants to common stock warrants upon the closing of the IPO (4,486 ) — Ending balance $ — $ 455 The valuation of the Company’s convertible preferred stock warrant liability contains unobservable inputs that reflect the Company’s own assumptions for which there was little, if any, market activity for at the measurement date. Accordingly, the Company’s convertible preferred stock warrant liability was measured at fair value in a recurring basis using unobservable inputs and are classified as Level 3 inputs, and any change in fair value was recognized as other expense in the statements of operations (see Note 11).

Inventories, Net

Inventories, Net	6 Months Ended
	Jun. 30, 2020
Inventory Disclosure [Abstract]
Inventories, Net	4. Inventories, net Inventories are net of reserves totaling $318,000 and $537,000 as of June 30, 2020 and December 31, 2019, respectively, and consist of the following (in thousands): June 30, 2020 December 31, 2019 Raw materials $ 1,817 $ 1,067 Work in process 911 640 Finished goods 2,892 2,246 $ 5,620 $ 3,953

Property and Equipment. net

Property and Equipment. net	6 Months Ended
	Jun. 30, 2020
Property Plant And Equipment [Abstract]
Property and Equipment. net	5. Property and Equipment. net Property and equipment consist of the following (in thousands): June 30, 2020 December 31, 2019 Manufacturing equipment $ 2,922 $ 2,190 Leasehold improvements 1,012 932 Computer software 351 296 Furniture and fixtures 389 259 Computer hardware 711 527 Assets in progress 643 406 6,028 4,610 Accumulated depreciation (1,852 ) (1,279 ) $ 4,176 $ 3,331 Depreciation expense of $218,000 and $95,000 was included in operating expenses and $81,000 and $22,000 was included in cost of goods sold for the three months ended June 30, 2020 and 2019, respectively. Depreciation expense of $418,000 and $185,000 was included in operating expenses and $155,000 and $43,000 was included in cost of goods sold for the six months ended June 30, 2020 and 2019, respectively. Capitalized Implementation Costs of a Hosting Arrangement The Company implemented a new enterprise resource planning, or ERP, system during 2019. The ERP system is a cloud-based hosting arrangement that is a service contract. The Company early and prospectively adopted ASU 2018-15, Intangibles—Goodwill and Other-Internal Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That is a Service Contract

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2020
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	6. Commitments and Contingencies Operating Leases In March 2019, the Company executed a five-year lease for a facility in Irvine, California, where all operations of the Company were moved when the Company obtained control of the facility in September 2019. The lease expires in September 2024 and contains two optional extension periods of five years each. In addition to the minimum future lease commitments presented below, the lease requires the Company to pay property taxes, insurance, maintenance, and repair costs. The lease includes a one-month rent holiday concession and escalation clauses for increased rent over the lease term. Rent expense is recognized using the straight-line method over the term of the lease. The Company records deferred rent calculated as the difference between rent expense and the cash rental payments. Rent expense under the lease agreements for the three months ended June 30, 2020 and 2019 was $170,000 and $51,000, respectively, and $324,000 and $101,000 for the six months ended June 30, 2020 and 2019, respectively. The Company also leases certain equipment under operating leases expiring in 2024. Future minimum commitments under all lease agreements are as follows : Year ending December 31: Amount Remainder of 2020 $ 304 2021 628 2022 656 2023 707 2024 601 $ 2,896 Indemnification In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and may provide for general indemnifications. The Company’s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future but have not yet been made. To date, the Company has not been subject to any claims or required to defend any action related to its indemnification obligations. The Company’s amended and restated certificate of incorporation contains provisions limiting the liability of directors, and its amended and restated bylaws provide that the Company will indemnify each of its directors to the fullest extent permitted under Delaware law. The Company’s amended and restated certificate of incorporation and amended and restated bylaws also provide its board of directors with discretion to indemnify its officers and employees when determined appropriate by the board. In addition, the Company has entered and expects to continue to enter into agreements to indemnify its directors and executive officers. Legal Proceedings From time to time, the Company may become involved in legal proceedings arising out of the ordinary course of its business. Management is currently not aware of any matters that will have a material adverse effect on the financial position, results of operations or cash flows of the Company.

Concentrations

Concentrations	6 Months Ended
	Jun. 30, 2020
Risks And Uncertainties [Abstract]
Concentrations	7. Concentrations All the Company’s revenue is derived from the sale of catheter-based therapeutic devices in the United States. For the three and six months ended June 30, 2020 and 2019, there were no customers which accounted for more than 10% of the Company’s revenue. There were no customers which accounted for more than 10% of the Company’s accounts receivable as of June 30, 2020 and December 31, 2019. No vendor accounted for more than 10% of the Company’s purchases for the three and six months ended June 30, 2020 and 2019. There were no vendors which accounted for more than 10% of the Company’s accounts payable as of June 30, 2020 and December 31, 2019.

Related Party

Related Party	6 Months Ended
	Jun. 30, 2020
Related Party Transactions [Abstract]
Related Party	8. Related Party Licensed Patents Certain stockholders of the Company are stockholders of Inceptus Medical, Inc. (“Inceptus”). Beginning in September 2011, the Company engaged Inceptus to develop the technology that has led to certain components used in the Company’s products, the FlowTriever and the ClotTriever systems. In October 2014, the Company, through a license agreement with Inceptus, obtained an exclusive, perpetual, fully paid-up irrevocable, worldwide license to the patents, patent applications and technology, including the right to grant and authorize sublicenses, to make, have made, use, sell, offer for sale, import and otherwise exploit products in connection with the licensed technology. The licensed technology is any and all technology involving a high wire count braid, excluding the tubular braiding subject to the sublicense agreement described below. Included in prepaid expenses and other current assets was a non-interest-bearing retainer paid by the Company to Inceptus. The retainer was applied to amounts owed by the Company to Inceptus at a time mutually agreed to by both parties. For three and six months ended June 30, 2019, the Company incurred development expenses with Inceptus of $3,000 and $6,000, respectively, which were applied against the balance of the retainer and included in research and development expense. In December 2019, Inceptus repaid in full to the Company the outstanding balance of the retainer. For the three and six months ended June 30, 2020, the Company incurred and paid development expenses with Inceptus of $9,000 and $13,000, respectively, which were included in research and development expense. Sublicense Agreement In August 2019, the Company entered into a sublicense agreement with Inceptus, pursuant to which Inceptus granted to the Company a non-transferable, worldwide, exclusive sublicense to its licensed intellectual property rights related to the tubular braiding for the non-surgical removal of clots and treatment of embolism and thrombosis in human vasculature other than carotid arteries, coronary vasculature and cerebral vasculature; such rights were originally granted to Inceptus pursuant to an intellectual property license agreement with Drexel University, or Drexel License, under which Drexel retained certain rights to use, and to permit other non-commercial entities to use, the sublicensed intellectual property for educational and non-commercial research purposes. The Company is obligated to comply with, and to avoid acts or omissions that would reasonably be likely to cause a breach of the Drexel License. The sublicense agreement will continue until the expiration of the sublicensed patent, unless terminated earlier pursuant to the terms of the agreement. The Company may terminate the sublicense agreement at any time by providing prior written notice. In connection with the sublicense agreement, during the year ended 2019 the Company paid Inceptus $139,000 for the reimbursement of expenses, milestone and administration fees. The Company was required to pay an ongoing quarterly administration fee of $18,000, which increased to $29,000 per quarter upon the completion of the Company’s IPO. Additionally, the Company is obligated to pay Inceptus an ongoing royalty ranging from 1% to 1.5% of the net sales of products utilizing the licensed intellectual property, subject to a minimum royalty quarterly fee of $1,000. For the three and six months ended June 30, 2020, the Company recorded royalty expense of $95,000 and $186,000, respectively, which is included in cost of goods sold. Other Services The Company utilizes MRI The Hoffman Group, a recruiting services company owned by the brother of the Chief Executive Officer and President and member of the board of directors of the Company. The Company paid for recruiting services provided by MRI The Hoffman Group amounting to $170,000 and $90,000 for the three months ended June 30, 2020 and 2019, respectively, and $249,000 and $170,000 for the six months ended June 30, 2020 and 2019, respectively. No amounts were due to MRI The Hoffman Group at June 30, 2020 and December 31, 2019.

Debt

Debt	6 Months Ended
	Jun. 30, 2020
Debt Disclosure [Abstract]
Debt	9. Debt The Company had the following outstanding debt, net of deferred financing costs and discounts, as of June 30, 2020 and December 31, 2019 (in thousands): June 30, 2020 December 31, 2019 Revolving line of credit $ 5,000 $ 5,000 Term loan 25,000 15,000 Final payment fee 250 150 Total notes payables 30,250 20,150 Unamortized discount and debt issuance costs (668 ) (669 ) Notes payable, net $ 29,582 $ 19,481 Credit Facility In December 2019, the Company entered into a $40 million credit facility with Signature Bank (the “SB Credit Facility”) and concurrently repaid and extinguished its term loan with East West Bank. The SB Credit Facility consists of a term loan of up to $25 million and a revolving line of credit of $15 million. The term loan is available in two tranches: a $15 million tranche that was fully funded on the closing date, and a $10 million tranche to be available through December 2020 subject to the Company’s achievement of at least $60 million of trailing 12-month revenue no later than August 2020. The Company used part of the proceeds from the first tranche to fully repay the $10 million term loan with East West Bank. In March 2020, the Company borrowed an additional $10 million which was available under the term loan. The maturity date of the new term loan is in December 2024. Under the agreement, the Company is required to make monthly interest payments through December 2021, subject to two six-month extensions to the interest-only period, which are available following the achievement of specified revenue milestones. The first extension is available upon the achievement by the Company of $100 million of trailing 12-month revenue within the initial interest-only period, and the second extension is available upon the achievement of $113 million of trailing 12-month revenue no later than June 30, 2022. Together, these extensions provide for a potential interest only-period of 36 months, through December 2022. The term loan bears interest at an annual rate equal to the greater of 5.50% or the Prime Rate plus 0.50%. Following the expiration of the interest-only period or any extension thereof, the Company will be required to repay the term loan in equal monthly installments of principal plus interest through maturity. Under the revolving line of credit, the Company may borrow, repay and re-borrow up to 80% of eligible accounts receivable up to a maximum of $15 million. The original maturity date of the revolving line of credit was in December 2022 and was extended to December 2024 when the Company completed its IPO. The Company is required to make monthly payments of interest only through maturity of the revolving line of credit, at which point the entire principal balance is due. The revolving line of credit bears interest at an annual rate equal to the greater of 5.00% or the prime rate. The Company paid a facility fee of $50,000 at time of closing and a final payment fee of 1.0% of the funded term loan amount will be payable at maturity, for which the Company recorded $250,000 and $150,000 as a liability as of June 30, 2020 and December 31, 2019, respectively. During the year ended December 31, 2019, the Company also paid a placement fee of $363,000 to a broker and approximately $124,000 in legal and other fees directly attributable to the new facility. The SB Credit Facility is secured by substantially all the Company’s assets, excluding intellectual property. The SB Credit Facility includes a double negative pledge on the Company’s intellectual property. The Company may prepay the SB Credit Facility at any time without any penalty or premium. The SB Credit Facility agreement contains minimum revenue financial covenants, measured monthly, which require the Company to achieve trailing 12-month revenue of $40 million no later than December 31, 2019 with incremental monthly increases to $60 million no later than December 31, 2020. Minimum revenue covenant levels will be set annually during the term of the SB Credit Facility by mutual agreement based on the Company’s annual forecast. The Company was in compliance with all debt covenants as of June 30, 2020. Maturities of the SB Credit Facility, including the 1.0% final payment fee, are as follows (in thousands): Year ending December 31: Amount 2020 $ — 2021 694 2022 8,333 2023 8,333 2024 12,890 Total future payments 30,250 Unamortized discount and debt issuance costs (668 ) Note payable $ 29,582 Deferred Financing Costs Costs incurred directly related to debt are presented as a reduction of the related debt instrument and amortized over the life of the related loan on an effective interest method as follows as of June 30, 2020 and December 31, 2019 (in thousands): June 30, 2020 December 31, 2019 Deferred financing costs $ 798 $ 686 Accumulated amortization (130 ) (17 ) Unamortized deferred financing costs $ 668 $ 669

Redeemable Convertible Preferre

Redeemable Convertible Preferred Stock	6 Months Ended
	Jun. 30, 2020
Temporary Equity Disclosure [Abstract]
Redeemable Convertible Preferred Stock	10. Redeemable Convertible Preferred Stock Redeemable convertible preferred stock (“convertible preferred stock”) consists of the following as of December 31, 2019 (in thousands, except share data): Shares Authorized Shares Issued and Outstanding Net Carrying Value Liquidation Value Series A 6,299,019 6,221,977 $ 8,777 $ 8,885 Series B 11,270,319 11,090,726 18,474 18,530 Series C 14,655,889 14,655,867 26,919 27,000 Total 32,225,227 31,968,570 $ 54,170 $ 54,415 In connection with the IPO in May 2020, the 31,968,570 shares of redeemable convertible preferred stock were converted into 31,968,570 shares of common stock, resulting in the reclassification of the related redeemable convertible preferred stock of $54.2 million to common stock and APIC. There are no redeemable convertible preferred stock outstanding as of June 30, 2020. As of December 31, 2019, the Company classified its Series A, Series B, and Series C convertible preferred stock outside of stockholders’ deficit as mezzanine equity because, the holders of redemption rights that were not within the Company’s control and in the event of certain “liquidation events” that were not solely within the control of the Company (including liquidation, sale or transfer of control of the Company), the shares would become redeemable at the option of the holders. As of December 31, 2019, the Company had not adjusted the carrying values of the convertible preferred stock to their deemed liquidation values of such shares since a liquidation event was not probable at the balance sheet date.

Stockholder's Equity

Stockholder's Equity	6 Months Ended
	Jun. 30, 2020
Equity [Abstract]
Stockholder's Equity	11. Stockholder’s Equity Authorized Stock As of December 31, 2019, the Company had authorized capital of 81,244,834 shares of stock, consisting of 49,019,607 shares of common stock, par value $0.001 per share, and 32,225,227 shares of Preferred Stock, par value $0.001 per share, 6,299,019 of which were designated Series A Preferred Stock, 11,270,319 of which were designated Series B Preferred Stock and 14,655,889 of which were designated Series C Preferred Stock. Upon the closing of the IPO in May 2020, and as of June 30, 2020, the Company had authorized 310,000,000 shares of stock, of which 300,000,000 shares are designated as common stock and 10,000,000 shares are designated as preferred stock. All stock has a par value of $0.001 per share. There are no shares of preferred stock outstanding as of June 30, 2020. Warrants The Company previously issued common stock warrants and redeemable convertible preferred stock warrants. Warrants issued and outstanding as of June 30, 2020 are as follows: Warrants Outstanding Number of warrants Exercise Price Expiration Common stock warrants 179,558 $ 1.67 4/28/2026 - 3/30/2027 Total outstanding warrants 179,558 Warrants issued and outstanding as of December 31, 2019 were as follows: Warrants Outstanding Number of warrants Exercise Price Expiration Common stock warrants 27,810 $ 0.14 10/19/2025 Series A preferred stock warrants 77,030 $ 1.43 12/10/2021 Series B preferred stock warrants 179,558 $ 1.67 4/28/2026 - 3/30/2027 Total preferred stock warrants 256,588 Total outstanding warrants 284,398 The Series A and Series B redeemable convertible preferred stock warrants (“Preferred Warrants”) allowed the holders to obtain shares of redeemable convertible preferred stock that contain a liquidation preference. Because this liquidation preference may have been payable in cash upon a change in control of the Company or upon exercise of redemption rights and because such a transaction was considered to be outside of the control of the Company, the Preferred Warrants were classified as liabilities on the accompanying balance sheets and were presented at their estimated fair values at each reporting date. On the completion of the IPO, all the outstanding Preferred Warrants were converted into warrants to purchase an aggregate of 256,588 shares of common stock, which resulted in the reclassification of the convertible preferred stock warrant liability to additional paid-in capital. In June 2020, 27,810 common stock warrants were exercised for cash. In addition, 77,030 warrants were net exercised and the Company issued 74,723 shares of common stock. The fair value of the Preferred Warrants was determined using the Black Scholes option pricing model with the following assumptions: May 21, 2020 (1) December 31, 2019 Series A Series B Series A Series B Expected volatility 51.10 % 50.00 % 41.40 % 39.80 % Preferred stock fair value (per share) $ 19.00 $ 19.00 $ 5.88 $ 5.94 Dividend yield 0.00 % 0.00 % 0.00 % 0.00 % Risk free interest rates 0.17 % 0.53 % 1.58 % 1.83 % Expected remaining term in years 1.55 5.94-6.86 1.95 6.33-7.25 (1) Date the Company’s registration statement on Form S-1 was declared effective

Equity Incentive Plan

Equity Incentive Plan	6 Months Ended
	Jun. 30, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Equity Incentive Plan	12. Equity Incentive Plan 2011 Equity Incentive Plan and 2020 Incentive Award Plan In 2011, the Company adopted the 2011 Equity Incentive Plan (the “2011 Plan”) to permit the grant of share-based awards, such as stock grants and incentives and non-qualified stock options to employees, directors, consultants and advisors. The Board has the authority to determine to whom awards will be granted, the number of shares, the term and the exercise price. In March 2020, the Company adopted the 2020 Incentive Award Plan (the “2020 Plan”), stock options, stock appreciation rights, awards of restricted stock and awards of restricted stock units Stock Options A summary of stock option activity under the 2011 Plan for the six months ended June 30, 2020 is as follows (intrinsic value in thousands): Number of Awards Weighted Average Exercise Price Weighted Average Fair Value Weighted Average Remaining Contractual Life (in years) Intrinsic Value Outstanding , December 31, 2019 4,082,302 $ 0.90 $ 0.74 8.76 $ 22,667 Granted 305,494 7.47 3.73 Exercised (135,263 ) 0.50 0.38 3,381 Cancelled (98,380 ) 8.50 3.63 1,007 Outstanding , June 30, 2020 4,154,153 $ 1.22 $ 0.90 8.37 $ 196,160 Vested and exercisable at June 30, 2020 1,508,051 $ 0.54 $ 0.46 7.87 $ 72,241 Vested and expected to vest at June 30, 2020 4,154,153 $ 1.22 $ 0.90 8.37 $ 196,160 The aggregate intrinsic values of options outstanding, vested and exercisable, and vested and expected to vest were calculated as the difference between the exercise price of the options and the estimated fair value of the Company’s common stock, as determined by the Board, as of December 31, 2019 and June 30, 2020. The fair value of each option grant was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions for the six months ended June 30, 2020 and 2019: 2020 2019 Expected volatility 40.60% 82.10% - 93.40% Weighted-average volatility 40.60% 92.07% Common stock fair value (per share) $7.88 - $9.05 $0.59 - $1.01 Dividend yield 0.00% 0.00% Risk free interest rates 1.46% - 1.68% 1.85% - 2.44% Expected remaining term in years 5.90 - 6.07 5.97 - 6.06 Restricted Stock Units In March 2019, the Company granted under the 2011 Plan, 2,867,326 restricted stock unit awards (“RSUs”) to certain employees that vest only upon the satisfaction of both a time-based service condition and a performance-based condition. The time-based service condition for these awards generally is satisfied over four years. The performance-based condition is a liquidity event requirement that was satisfied on the effective date of the IPO of the Company’s common stock. The RSUs vest on the first date upon which both the service-based and performance-based requirements are satisfied. If the RSUs vest, the actual number of RSUs that will vest will be dependent on the per share value of the Company’s common stock, which is a market-based condition, determined based on the average closing price of the Company’s common stock for the three-month period immediately preceding the satisfaction of the service condition. The probabilities of the actual number of RSUs expected to vest are reflected in the grant date fair values, and the compensation expense for these awards will be recognized assuming the requisite service period is rendered, and only if the performance-based condition is considered probable to be satisfied. Through May 21, 2020, no stock-based compensation expense had been recognized for these awards because the liquidity event performance condition described above for the RSUs was not considered probable of being satisfied. Upon the completion of the Company’s IPO, the Company recognized $159,000 of stock-based compensation expense related to such awards. 2020 Plan RSUs are share awards that entitle the holder to receive freely tradable shares of the Company’s common stock upon vesting. The RSUs cannot be transferred and the awards are subject to forfeiture if the holder’s employment terminates prior to the release of the vesting restrictions. The RSUs generally vest over a four-year period with straight-line vesting and a 25% one year cliff or over a three year period in equal amounts on a quarterly basis, provided the employee remains continuously employed with the Company. The fair value of the RSUs is equal to the closing price of the Company’s common stock on the grant date. RSU activity under the 2020 Plan is set forth below (intrinsic value in thousands) : Number of Awards Weighted Average Fair Value Intrinsic Value Outstanding , December 31, 2019 — $ — $ — Granted 104,538 49.25 5,128 Outstanding , June 30, 2020 104,538 $ 49.25 $ 50,638 Vested and exercisable at June 30, 2020 — $ — $ — Vested and expected to vest at June 30, 2020 104,538 $ 49.25 $ 50,638 Total compensation cost for all share-based payment arrangements recognized was as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Cost of goods sold $ 42 $ 9 $ 72 $ 12 Research and development 77 21 124 40 Selling, general and administrative 386 69 804 138 $ 505 $ 99 $ 1,000 $ 190 Total compensation costs as of June 30, 2020 related to all non-vested awards to be recognized in future periods was $7,967,000 and is expected to be recognized over the weighted average period of 3.4 years. Employee Share Purchase Plan (ESPP) In May 2020, the Company adopted the 2020 Employee Stock Purchase Plan (“ESPP”), which became effective on the date the ESPP was adopted by the Company’s board of directors. The Company has initially reserved 990,870 shares of common stock for purchase under the ESPP. Each offering to the employees to purchase stock under the ESPP will begin on each August 1 and February 1 and will end on the following January 31 and July 31, respectively. The first offering period is expected to begin on August 1, 2020 and end on January 31, 2021.

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2020
Income Tax Disclosure [Abstract]
Income Taxes	14. Income Taxes The following table reflects the Company’s provision (benefit) for income taxes for the periods indicated (in thousands): Three Months Ended Six Months Ended June 30, 2020 2019 2020 2019 Income (loss) before taxes $ (3,804 ) $ (965 ) $ 308 $ (1,913 ) Income tax provision (benefit) — — — — Net income (loss) $ (3,804 ) $ (965 ) $ 308 $ (1,913 ) Income tax provision (benefit) as a percentage of income taxes 0.00 % 0.00 % 0.00 % 0.00 % The Company’s effective tax rate is driven by pre-tax income (loss), business credits, net operating loss carryforwards, and the valuation allowance. No tax provision (benefit) was recorded for the three and six months ended June 30, 2020 and 2019. Valuation Allowance ASC 740 requires that the tax benefit of net operating losses, or NOLs, temporary differences and credit carryforwards be recorded as an asset to the extent that management assesses that realization is “more likely than not.” Realization of the future tax benefits is dependent on the Company’s ability to generate sufficient taxable income within the carryback or carryforward periods. Management believes that recognition of the deferred tax assets arising from the above-mentioned tax benefits from NOLs and credit carryforwards is currently not likely to be realized and, accordingly, has provided a valuation allowance against its deferred tax assets. Uncertain Tax Positions The Company has recorded uncertain tax positions related to its federal and California research and development credit carryforwards. No interest or penalties have been recorded related to the uncertain tax positions due to other available NOLs to offset the uncertain tax positions. It is not expected that there will be a significant change in uncertain tax position in the next 12 months. The Company is subject to U.S. federal and state income tax as well as to income tax in multiple state jurisdictions, and various foreign jurisdictions. In the normal course of business, the Company is subject to examination by tax authorities. As of the date of the financial statements, there are no tax examinations in progress. The statute of limitations for tax years ended after December 31, 2015 and December 31, 2016 are open for state and federal tax purposes, respectively. CARES Act The Coronavirus Aid, Relief, and Economic Security, or CARES, Act became effective on March 27, 2020. It was a response to the market volatility and instability resulting from the coronavirus pandemic and includes provisions to support businesses in the form of loans, grants, and tax changes, among other types of relief. The Company has reviewed the income tax changes included in the CARES Act, which primarily includes the expansion of the carryback period for NOLs, changes to the deduction and limitation on interest, and acceleration of depreciation for Qualified Improvement Property. The Company has analyzed these changes and does not believe there will be a material effect on the Company’s income tax provision. The Company currently does not expect to apply for loans or grants under the CARES Act.

Retirement Plan

Retirement Plan	6 Months Ended
	Jun. 30, 2020
Compensation And Retirement Disclosure [Abstract]
Retirement Plan	15. Retirement Plan In December 2017, the Company adopted the Inari Medical, Inc. 401(k) Plan which allows eligible employees after one month of service to contribute pre-tax and Roth contributions to the plan, as allowed by law. The plan assets are held by Vanguard and the plan administrator is Ascensus. The Company does not currently make fund-matching contributions.

Net Loss Per Share

Net Loss Per Share	6 Months Ended
	Jun. 30, 2020
Earnings Per Share [Abstract]
Net Loss Per Share	16. Net Loss Per Share The following outstanding potentially dilutive common stock equivalents have been excluded from the calculation of diluted net loss per share for the periods presented due to their anti-dilutive effect: For the Three Months Ended June 30, For the Six Months Ended June 30, 2020 2019 2020 2019 Convertible preferred stock 18,267,754 31,968,570 — 31,968,570 Common stock options 4,154,153 3,949,631 — 3,949,631 RSUs 2,971,864 2,867,326 — 2,867,326 Restricted stock subject to future vesting 239,861 566,259 — 566,259 Convertible preferred stock warrants — 256,588 — 256,588 Common stock warrants 179,558 27,810 — 27,810 25,813,190 39,636,184 — 39,636,184

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
COVID-19 and CARES Act	COVID-19 and CARES Act The Company has been actively monitoring the novel coronavirus, or COVID-19, situation and its impact. In response to the pandemic, numerous state and local jurisdictions have imposed “shelter-in-place” orders, quarantines and other restrictions. In the United States, governmental authorities have recommended, and in certain cases required, that elective, specialty and other procedures and appointments, be suspended or canceled. Similarly, in March 2020, the governor of California, where the Company’s headquarters are located, issued “stay at home” orders limiting non-essential activities, travel and business operations. Such orders or restrictions have resulted in reduced operations at the Company’s headquarters, work stoppages, slowdowns and delays, travel restrictions and cancellation of events. These orders and restrictions have significantly decreased the number of procedures performed using the Company’s products and otherwise negatively impacted operations. In response to the impact of COVID-19, the Company implemented a variety of measures intended to help manage through the impact and position it to resume operations quickly and efficiently once these restrictions are lifted. Some of these measures include: adapting, expanding and improving various sales, physician outreach and training programs to address the current environment; producing approximately four months’ worth of inventory before temporarily suspending production and executing a work from home strategy for administrative functions. The impact of COVID-19 is changing daily and cannot be predicted. As a result, the Company expects the pandemic to continue to negatively impact its business, financial condition and results of operations. On March 27, 2020, the President signed into law the “Coronavirus Aid, Relief, and Economic Security (CARES) Act.” The CARES Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations, increased limitations on qualified charitable contributions, and technical corrections to tax depreciation methods for qualified improvement property. The Company currently may be eligible but has not taken advantage of the payroll protection program, emergency grants and business loans under the CARES Act. The Company expects to monitor the impact that the CARES Act may have on its business, financial condition, results of operations, or liquidity.
Basis of Presentation of Unaudited Interim Condensed Consolidated Financial Statements	Basis of Presentation of Unaudited Interim Condensed Consolidated Financial Statements The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Certain prior year reported amounts have been reclassified to conform with the 2020 presentation. The interim condensed consolidated balance sheet as of June 30, 2020, the condensed consolidated statements of operations, m ezzanine equity and stockholders’ deficit, filed pursuant to Rule 424(b)(4) with the U.S. Securities and Exchange Commission on May 26, 2020
Principles of Consolidation	Principles of Consolidation In May 2020, the Company formed Inari Medical International, Inc., a wholly-owned subsidiary incorporated in Delaware. All intercompany balances and transactions have been eliminated in consolidation.
Management Estimates	Management Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant estimates and assumptions made in the accompanying financial statements include, but are not limited to the collectability of receivables, valuation of inventory, the fair value of common stock warrants, the fair value of preferred stock warrant liabilities, the fair value of stock options, recoverability of the Company’s net deferred tax assets, and related valuation allowance and certain accruals. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates.
JOBS Act Accounting Election	JOBS Act Accounting Election As an emerging growth company under the Jumpstart Our Business Startups Act of 2012 ("the JOBS Act"), the Company is eligible to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies. the Company has elected to take advantage of the extended transition period for adopting new or revised accounting standards that have different effective dates for public and private companies until such time as those standards apply to private companies.
Cash, Cash Equivalents and Restricted Cash	Cash, Cash Equivalents and Restricted Cash The Company considers cash on hand, cash in demand deposit accounts including money market funds, and instruments with a maturity date of 90 days or less at date of purchase to be cash and cash equivalents. The Company maintains its cash, cash equivalent and restricted cash balances with banks. Under the Dodd-Frank Wall Street Reform and Consumer Protection Act, deposits of up to $250,000 at FDIC-insured institutions are covered by FDIC insurance. At times, deposits may be in excess of the FDIC insurance limit; however, management does not believe the Company is exposed to any significant related credit risk. Restricted cash as of June 30, 2020 and December 31, 2019 consisted of a cash secured letter of credit in the amount of $338,000 representing collateral for the Company’s facility lease. Restricted cash additionally included as of June 30, 2020 and December 31, 2019, a compensating balance of $50,000 to secure the Company’s corporate purchasing cards.
Accounts Receivable, Net	Accounts Receivable, net Trade accounts receivable are recorded at the invoiced amount, net of any allowance for doubtful accounts. Any allowance for doubtful accounts is developed based upon several factors including the customers’ credit quality, historical write-off experience and any known specific issues or disputes which exist as of the balance sheet date. Account receivable balances are written off against the allowance after appropriate collection efforts are exhausted. The allowance for doubtful accounts was $146,000 and $62,000 as of June 30, 2020 and December 31, 2019, respectively, and no accounts receivable write offs were recognized during the three and six months ended June 30, 2020 and 2019. Despite the Company’s efforts to minimize credit risk exposure, customers could be adversely affected if future economic and industry trends, including those related to COVID-19, change in such a manner as to negatively impact their cash flows. The full effects of COVID-19 on the Company’s customers are highly uncertain and cannot be predicted. As a result, the Company’s future collection experience can differ significantly from historical collection trends. If the Company’s clients experience a negative impact on their cash flows, it could have a material adverse effect on the Company’s results of operations and financial condition.
Inventories, Net	Inventories, net The Company values inventory at the lower of the actual cost to purchase or manufacture the inventory or net realizable value for such inventory. Cost, which includes material, labor and overhead costs, is determined on the first-in, first out method, or FIFO. The Company regularly reviews inventory quantities in process and on hand, and when appropriate, records a provision for obsolete and excess inventory. The Company writes down inventory that has become obsolete, inventory that has a cost basis in excess of its expected net realizable value and inventory in excess of expected requirements based on future demand and as compared to remaining shelf life. The estimate of excess quantities is subjective and primarily dependent on the Company’s estimates of future demand for a particular product. If the estimate of future demand is inaccurate based on actual sales, the Company may increase the write down for excess inventory for that component and record a charge to inventory impairment in the accompanying condensed consolidated statement of operations and comprehensive income (loss).
Property and Equipment	Property and Equipment Property and equipment are stated at cost. Additions and improvements that extend the lives of the assets are capitalized while expenditures for repairs and maintenance are expensed as incurred. Depreciation is provided using the straight-line method over the estimated useful lives of the assets, ranging from three to seven years. Leasehold improvements are depreciated over the shorter of the useful life of the improvement or the lease term, including renewal periods that are reasonably assured. Upon sale or disposition of property and equipment, any gain or loss is included in the accompanying statement of operations.
Deferred Initial Public Offering Costs	Deferred Initial Public Offering Costs Specific incremental legal, accounting and other fees and costs directly attributable to a proposed or actual offering of securities may properly be deferred and charged against the gross proceeds of the offering. As of December 31, 2019, there were approximately $1,382,000 of offering costs, primarily consisting of legal, accounting and printing fees, which were capitalized in other non-current assets on the balance sheet. In May 2020, upon the closing of the IPO, total deferred costs of approximately $3,701,000 were offset against the Company’s IPO proceeds.
Impairment of Long-lived Assets	Impairment of Long-lived Assets The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparing the carrying amount to the future net undiscounted cash flows which the assets are expected to generate. If such assets are considered impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows arising from the asset. The Company has not identified any such impairment losses to date.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company’s cash, cash equivalents and restricted cash, accounts receivable, accounts payable and accrued liabilities approximate their fair value due to their liquidity or short maturities. Management believes that its long term debt bears interest at the prevailing market rates for instruments with similar characteristics; accordingly, the carrying value of this instrument approximates its fair value as of June 30, 2020 and December 31, 2019. The Company measures and records certain financial assets and liabilities at fair value on a recurring basis. U.S. GAAP provides a fair value hierarchy that distinguishes between (i) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (ii) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels. • Level 1—Quoted prices in active markets for identical assets or liabilities. • Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. • Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of assets or liabilities. See Note 3 for further information.
Convertible Preferred Stock Warrant Liability	Convertible Preferred Stock Warrant Liability The Company has accounted for its freestanding warrants to purchase shares of the Company’s convertible preferred stock as liabilities at fair value upon issuance primarily because the preferred shares underlying the warrants contain contingent redemption features outside the control of the Company. The warrants are subject to remeasurement at each balance sheet date and any change in fair value is recognized as the change in fair value of warrant liability and recorded to other expense in the statements of operations. The carrying value of the warrants continued to be adjusted until the completion of the IPO, which occurred in May 2020. At that time, the preferred stock warrant liability was adjusted to fair value and reclassified to additional paid-in capital, a component of stockholders’ equity (deficit) (see Note 3).
Revenue Recognition	Revenue Recognition On January 1, 2019, the Company adopted Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers, Under ASC 606, revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. Product sales of the FlowTriever and ClotTriever systems are made to hospitals in the United States utilizing the Company’s direct sales force. Revenue is comprised of product revenue net of returns, administration fees and sales rebates. Performance Obligation —The Company has revenue arrangements that consist of a single performance obligation, delivery of the Company’s products. The satisfaction of this performance obligation occurs with the transfer of control of the Company’s product to its customers, either upon shipment or delivery of the product. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring goods. The amount of revenue that is recognized is based on the transaction price, which represents the invoiced amount and includes estimates of variable consideration such as rebate and administrative fees, where applicable. The Company provides a 30-day unconditional right of return period. The Company establishes estimated provisions for returns at the time of sale based on historical experience. Historically, the actual product returns have been immaterial to the Company’s financial statements. Assuming all other revenue recognition criteria have been met, the Company recognizes revenue for arrangements where the Company has satisfied its performance obligation of delivering the product. For sales where the Company’s sales representatives hand deliver products directly to the hospital, control of the products transfers to the customer upon such hand delivery. For sales where products are shipped, control of the products transfers either upon shipment or delivery of the products to the customer, depending on the shipping terms and conditions. As of June 30, 2020 and December 31, 2019, the Company recorded $302,000 and $330,000, respectively, of unbilled receivables, which are included in accounts receivable, net, in the accompanying balance sheet. For both the three months ended June 30, 2020 and 2019, 40% of revenue was derived from the sale of ClotTriever products, and 60% of revenue was derived from the sale of FlowTriever products. For the six months ended June 30, 2020 and 2019, 38% and 39% of revenue was derived from the sale of ClotTriever products, respectively, and 62% and 61% of revenue was derived from the sale of FlowTriever products, respectively. The Company offers payment terms to its customer of less than three months and these terms do not include a significant financing component. The Company excludes taxes assessed by governmental authorities on revenue-producing transactions from the measurement of the transaction price. The Company offers its standard warranty to all customers and no warranties are available for sale on a standalone basis. The Company’s warranty provides that its products are free of material defects and conform to specifications, and offer to repair, replace or refund the purchase price of defective products. This assurance does not constitute a service and is not considered a separate performance obligation. The Company estimates warranty liabilities at the time of revenue recognition and records it as a charge to cost of goods sold. Costs associated with product sales include commissions and are recorded in selling, general and administrative expenses. The Company applies the practical expedient and recognizes commissions as expense when incurred because the amortization period is less than one year.
Cost of Goods Sold	Cost of Goods Sold Cost of goods sold consists primarily of the cost of raw materials, components, direct labor and manufacturing overhead. Overhead costs include the cost of quality assurance, material procurement, inventory control, facilities, equipment and operations supervision and management, including stock-based compensation. Cost of goods sold also includes depreciation expense for production equipment and certain direct costs such as shipping costs and royalty expense.
Shipping Costs	Shipping Costs Shipping costs billed to customers are not included in revenue, and are reported as a reduction of costs of goods sold.
Advertising Costs	Advertising Costs Advertising costs are charged to operations as incurred. Advertising costs were $74,000 and $6,000 for the three months ended June 30, 2020 and 2019, respectively and $111,000 and $34,000 for the six months ended June 30, 2020 and 2019, respectively. Advertising costs are included in selling, general and administrative expenses in the accompanying statements of operations.
Research and Development	Research and Development Research and development costs are expensed as incurred and include the costs to design, develop, test, deploy and enhance new and existing products. Research and development costs also include expenses associated with clinical studies, registries and sponsored research. These costs include direct salary and employee benefit related costs for research and development personnel, costs for materials used and costs for outside services.
Patent-Related Expenditures	Patent-related Expenditures Expenditures related to patent research and applications, which are primarily legal fees, are expensed as incurred and are included in selling, general and administrative expenses in the accompanying statements of operations.
Stock-based Compensation	Stock-based Compensation The Company’s employee and non-employee share-based awards result in a cost that is measured at fair value on the awards’ grant date, based on the estimated number of awards that are expected to vest. Stock-based compensation is recognized over the service period.
Income Taxes	Income Taxes The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Management assesses the likelihood that the resulting deferred tax assets will be realized. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. Due to the Company’s historical operating performance and the recorded cumulative net losses in prior fiscal periods, the net deferred tax assets have been fully offset by a valuation allowance. The Company recognizes uncertain income tax positions at the largest amount that is more likely than not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. Changes in recognition or measurement are reflected in the period in which judgment occurs. The Company’s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of provision for income taxes.
Foreign Currency Transactions	Foreign Currency Transactions Certain vendors are paid in currencies other than the US dollar. Transaction gains and losses are included in selling, general and administrative expenses.
Comprehensive Income (Loss)	Comprehensive Income (Loss) The Company’s net income (loss) equaled comprehensive income (loss) for the three and six months ended June 30, 2020 and 2019.
Net Income (Loss) per Share of Common Stock	Net Income (Loss) per Share of Common Stock Basic net income (loss) per share is computed by dividing the net income (loss) attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period, without consideration for potential dilutive common shares. Diluted net income (loss) per share is computed by dividing the net income (loss) attributable to common stockholders by the weighted average number of shares of common stock and potentially dilutive securities outstanding for the period. For purposes of the diluted net income (loss) per share calculation, redeemable convertible preferred stock and warrants, and common stock options are considered to be potentially dilutive securities. For the periods the Company is in a net loss position, basic net loss per share is the same as diluted net loss per share as the inclusion of all potential dilutive common shares would have been anti-dilutive. The Company allocates no loss to participating securities because they have no contractual obligation to share in the losses of the Company. The shares of the Company’s convertible preferred stock participate in any dividends declared by the Company and are therefore considered to be participating securities.
Segment Reporting	Segment Reporting Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (“CODM”) in deciding how to allocate resources to an individual segment and in assessing performance. The Company’s CODM is its Chief Executive Officer. The Company has determined it operates in one segment - the development and commercialization of innovative and minimally invasive mechanical thrombectomy devices to treat thromboembolism in the venous system. Geographically, we sell to hospitals in the United States. Segment information is consistent with how management reviews the business, makes investing and resource allocation decisions and assesses operating performance.
Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements	Recently Adopted Accounting Pronouncements In June 2018, the FASB issued ASU No. 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting Recent Accounting Pronouncements In February 2017, the FASB issued ASU 2017-02, Leases In June 2016, the FASB issued ASU 2016-13 “ Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2020
Fair Value Disclosures [Abstract]
Schedule of Financial Assets and Liabilities Measured at Fair Value	The following tables summarize the Company’s financial assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy as of June 30, 2020 and December 31, 2019 (in thousands): December 31, 2019 Level 1 Level 2 Level 3 Total Liabilities: Convertible preferred stock warrant liability $ — $ — $ 1,169 $ 1,169 Total liabilities $ — $ — $ 1,169 $ 1,169 June 30, 2020 Level 1 Level 2 Level 3 Total Liabilities: Convertible preferred stock warrant liability $ — $ — $ — $ - Total liabilities $ — $ — $ - $ -
Schedule of Change in the Fair Value of the Warrant Liability	The change in the fair value of the warrant liability is summarized below (in thousands): Six Months Ended June 30, 2020 2019 Beginning balance $ 1,169 $ 213 Change in fair value of warrant liability 3,317 242 Conversion of preferred stock warrants to common stock warrants upon the closing of the IPO (4,486 ) — Ending balance $ — $ 455

Inventories, Net (Tables)

Inventories, Net (Tables)	6 Months Ended
	Jun. 30, 2020
Inventory Disclosure [Abstract]
Schedule of Inventories, Net	Inventories are net of reserves totaling $318,000 and $537,000 as of June 30, 2020 and December 31, 2019, respectively, and consist of the following (in thousands): June 30, 2020 December 31, 2019 Raw materials $ 1,817 $ 1,067 Work in process 911 640 Finished goods 2,892 2,246 $ 5,620 $ 3,953

Property and Equipment. net (Ta

Property and Equipment. net (Tables)	6 Months Ended
	Jun. 30, 2020
Property Plant And Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment consist of the following (in thousands): June 30, 2020 December 31, 2019 Manufacturing equipment $ 2,922 $ 2,190 Leasehold improvements 1,012 932 Computer software 351 296 Furniture and fixtures 389 259 Computer hardware 711 527 Assets in progress 643 406 6,028 4,610 Accumulated depreciation (1,852 ) (1,279 ) $ 4,176 $ 3,331

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2020
Commitments And Contingencies Disclosure [Abstract]
Schedule of Future Minimum Commitments	Future minimum commitments under all lease agreements are as follows : Year ending December 31: Amount Remainder of 2020 $ 304 2021 628 2022 656 2023 707 2024 601 $ 2,896

Debt (Tables)

Debt (Tables)	6 Months Ended
	Jun. 30, 2020
Debt Disclosure [Abstract]
Schedule of Outstanding Debt, Net of Deferred Financing Costs and Discounts	The Company had the following outstanding debt, net of deferred financing costs and discounts, as of June 30, 2020 and December 31, 2019 (in thousands): June 30, 2020 December 31, 2019 Revolving line of credit $ 5,000 $ 5,000 Term loan 25,000 15,000 Final payment fee 250 150 Total notes payables 30,250 20,150 Unamortized discount and debt issuance costs (668 ) (669 ) Notes payable, net $ 29,582 $ 19,481
Schedule of Maturities of SB Credit Facility	Maturities of the SB Credit Facility, including the 1.0% final payment fee, are as follows (in thousands): Year ending December 31: Amount 2020 $ — 2021 694 2022 8,333 2023 8,333 2024 12,890 Total future payments 30,250 Unamortized discount and debt issuance costs (668 ) Note payable $ 29,582
Schedule of Deferred Financing Costs	Costs incurred directly related to debt are presented as a reduction of the related debt instrument and amortized over the life of the related loan on an effective interest method as follows as of June 30, 2020 and December 31, 2019 (in thousands): June 30, 2020 December 31, 2019 Deferred financing costs $ 798 $ 686 Accumulated amortization (130 ) (17 ) Unamortized deferred financing costs $ 668 $ 669

Redeemable Convertible Prefer_2

Redeemable Convertible Preferred Stock (Tables)	6 Months Ended
	Jun. 30, 2020
Temporary Equity Disclosure [Abstract]
Schedule of Redeemable Convertible Preferred Stock	Redeemable convertible preferred stock (“convertible preferred stock”) consists of the following as of December 31, 2019 (in thousands, except share data): Shares Authorized Shares Issued and Outstanding Net Carrying Value Liquidation Value Series A 6,299,019 6,221,977 $ 8,777 $ 8,885 Series B 11,270,319 11,090,726 18,474 18,530 Series C 14,655,889 14,655,867 26,919 27,000 Total 32,225,227 31,968,570 $ 54,170 $ 54,415

Stockholder's Equity (Tables)

Stockholder's Equity (Tables)	6 Months Ended
	Jun. 30, 2020
Equity [Abstract]
Schedule of Warrants Issued and Outstanding	Warrants issued and outstanding as of June 30, 2020 are as follows: Warrants Outstanding Number of warrants Exercise Price Expiration Common stock warrants 179,558 $ 1.67 4/28/2026 - 3/30/2027 Total outstanding warrants 179,558 Warrants issued and outstanding as of December 31, 2019 were as follows: Warrants Outstanding Number of warrants Exercise Price Expiration Common stock warrants 27,810 $ 0.14 10/19/2025 Series A preferred stock warrants 77,030 $ 1.43 12/10/2021 Series B preferred stock warrants 179,558 $ 1.67 4/28/2026 - 3/30/2027 Total preferred stock warrants 256,588 Total outstanding warrants 284,398
Schedule of Fair Value of Preferred Warrants Determined Using Black Scholes Option Pricing Model	The fair value of the Preferred Warrants was determined using the Black Scholes option pricing model with the following assumptions: May 21, 2020 (1) December 31, 2019 Series A Series B Series A Series B Expected volatility 51.10 % 50.00 % 41.40 % 39.80 % Preferred stock fair value (per share) $ 19.00 $ 19.00 $ 5.88 $ 5.94 Dividend yield 0.00 % 0.00 % 0.00 % 0.00 % Risk free interest rates 0.17 % 0.53 % 1.58 % 1.83 % Expected remaining term in years 1.55 5.94-6.86 1.95 6.33-7.25 (1) Date the Company’s registration statement on Form S-1 was declared effective

Equity Incentive Plan (Tables)

Equity Incentive Plan (Tables)	6 Months Ended
	Jun. 30, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Summary of Stock Option Activity	A summary of stock option activity under the 2011 Plan for the six months ended June 30, 2020 is as follows (intrinsic value in thousands): Number of Awards Weighted Average Exercise Price Weighted Average Fair Value Weighted Average Remaining Contractual Life (in years) Intrinsic Value Outstanding , December 31, 2019 4,082,302 $ 0.90 $ 0.74 8.76 $ 22,667 Granted 305,494 7.47 3.73 Exercised (135,263 ) 0.50 0.38 3,381 Cancelled (98,380 ) 8.50 3.63 1,007 Outstanding , June 30, 2020 4,154,153 $ 1.22 $ 0.90 8.37 $ 196,160 Vested and exercisable at June 30, 2020 1,508,051 $ 0.54 $ 0.46 7.87 $ 72,241 Vested and expected to vest at June 30, 2020 4,154,153 $ 1.22 $ 0.90 8.37 $ 196,160
Schedule of Estimated Fair Value of Option Grant on Date of Grant	The fair value of each option grant was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions for the six months ended June 30, 2020 and 2019: 2020 2019 Expected volatility 40.60% 82.10% - 93.40% Weighted-average volatility 40.60% 92.07% Common stock fair value (per share) $7.88 - $9.05 $0.59 - $1.01 Dividend yield 0.00% 0.00% Risk free interest rates 1.46% - 1.68% 1.85% - 2.44% Expected remaining term in years 5.90 - 6.07 5.97 - 6.06
Summary of RSU Activity	RSU activity under the 2020 Plan is set forth below (intrinsic value in thousands) : Number of Awards Weighted Average Fair Value Intrinsic Value Outstanding , December 31, 2019 — $ — $ — Granted 104,538 49.25 5,128 Outstanding , June 30, 2020 104,538 $ 49.25 $ 50,638 Vested and exercisable at June 30, 2020 — $ — $ — Vested and expected to vest at June 30, 2020 104,538 $ 49.25 $ 50,638
Schedule of Total Compensation Cost for All Share-Based Payment Arrangements Recognized	Total compensation cost for all share-based payment arrangements recognized was as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Cost of goods sold $ 42 $ 9 $ 72 $ 12 Research and development 77 21 124 40 Selling, general and administrative 386 69 804 138 $ 505 $ 99 $ 1,000 $ 190

Income Taxes (Tables)

Income Taxes (Tables)	6 Months Ended
	Jun. 30, 2020
Income Tax Disclosure [Abstract]
Schedule of Provision (Benefit) for Income Taxes	The following table reflects the Company’s provision (benefit) for income taxes for the periods indicated (in thousands): Three Months Ended Six Months Ended June 30, 2020 2019 2020 2019 Income (loss) before taxes $ (3,804 ) $ (965 ) $ 308 $ (1,913 ) Income tax provision (benefit) — — — — Net income (loss) $ (3,804 ) $ (965 ) $ 308 $ (1,913 ) Income tax provision (benefit) as a percentage of income taxes 0.00 % 0.00 % 0.00 % 0.00 %

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	6 Months Ended
	Jun. 30, 2020
Earnings Per Share [Abstract]
Schedule of Outstanding Potentially Dilutive Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share	The following outstanding potentially dilutive common stock equivalents have been excluded from the calculation of diluted net loss per share for the periods presented due to their anti-dilutive effect: For the Three Months Ended June 30, For the Six Months Ended June 30, 2020 2019 2020 2019 Convertible preferred stock 18,267,754 31,968,570 — 31,968,570 Common stock options 4,154,153 3,949,631 — 3,949,631 RSUs 2,971,864 2,867,326 — 2,867,326 Restricted stock subject to future vesting 239,861 566,259 — 566,259 Convertible preferred stock warrants — 256,588 — 256,588 Common stock warrants 179,558 27,810 — 27,810 25,813,190 39,636,184 — 39,636,184

Organization - Additional Infor

Organization - Additional Information (Details) $ / shares in Units, $ in Thousands	1 Months Ended			6 Months Ended
	May 31, 2020USD ($)$ / sharesshares	Mar. 31, 2020	Dec. 31, 2019USD ($)$ / sharesshares	Jun. 30, 2020USD ($)$ / sharesshares	May 27, 2020shares
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Net proceeds from IPO | $	$ 163,000			$ 164,361
Underwriters’ discounts and commissions | $	12,600
Offering costs | $	$ 3,700
Offering cost incurred | $			$ 1,400
Preferred stock converted into common stock	31,968,570
Common stock, shares authorized			49,019,607	300,000,000
Common stock, par value | $ / shares			$ 0.001	$ 0.001
Preferred stock, shares authorized			10,000,000	10,000,000
Preferred stock, par value | $ / shares			$ 0.001	$ 0.001
Reverse stock split, conversion ratio	0.833333333	0.840336134
Redeemable Convertible Preferred Stock Warrants
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Converted into warrants to purchase common stock	256,588				256,588
Series A B and C Redeemable Convertible Preferred Stock
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Preferred stock converted into common stock	31,968,570
Preferred stock, conversion basis				Upon the completion of the IPO, all shares of Series A, B, and C redeemable convertible preferred stock then outstanding were converted into 31,968,570 shares of common stock on a one-to-one basis.
IPO
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Stock issued	9,432,949
Public offering price | $ / shares	$ 19
Common stock, shares authorized	300,000,000
Common stock, par value | $ / shares	$ 0.001
Preferred stock, shares authorized	10,000,000
Preferred stock, par value | $ / shares	$ 0.001
Over-allotment Option
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Sale of stock, shares issued	1,230,384

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	May 31, 2020	Dec. 31, 2019
Summary of Significant Accounting Policies [Line Items]
Restricted cash as collateral for facility lease	$ 338,000		$ 338,000			$ 338,000
Restricted cash to secure corporate purchasing cards	50,000		50,000			50,000
Allowance for doubtful accounts	146,000		146,000			62,000
Accounts receivable write offs	$ 0	$ 0	$ 0	$ 0
Deferred initial public offering costs					$ 3,701,000
Accounting Standards Update 2018-07
Summary of Significant Accounting Policies [Line Items]
Change in accounting principle, accounting standards update, adopted	true		true
Change in accounting principle, accounting standards update, adoption date	Jan. 1, 2020		Jan. 1, 2020
Change in accounting principle, accounting standards update, immaterial effect	true		true
Selling, General and Administrative Expenses
Summary of Significant Accounting Policies [Line Items]
Advertising costs	$ 74,000	$ 6,000	$ 111,000	$ 34,000
ClotTriever Products
Summary of Significant Accounting Policies [Line Items]
Percentage of revenue	40.00%	40.00%	38.00%	39.00%
FlowTriever Products
Summary of Significant Accounting Policies [Line Items]
Percentage of revenue	60.00%	60.00%	62.00%	61.00%
Other Noncurrent Assets
Summary of Significant Accounting Policies [Line Items]
Deferred initial public offering costs						1,382,000
Accounts Receivable, Net
Summary of Significant Accounting Policies [Line Items]
Unbilled receivables	$ 302,000		$ 302,000			330,000
Leasehold Improvements
Summary of Significant Accounting Policies [Line Items]
Estimated useful lives			shorter of the useful life of the improvement or the lease term
Cash Secured Letter of Credit
Summary of Significant Accounting Policies [Line Items]
Restricted cash as collateral for facility lease	338,000		$ 338,000			$ 338,000
Maximum
Summary of Significant Accounting Policies [Line Items]
Deposits, FDIC insured amount	$ 250,000		$ 250,000
Estimated useful lives of assets			7 years
Minimum
Summary of Significant Accounting Policies [Line Items]
Estimated useful lives of assets			3 years

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair Value (Details) - Fair Value Measurements Recurring $ in Thousands	Dec. 31, 2019USD ($)
Liabilities:
Total liabilities	$ 1,169
Convertible Preferred Stock Warrants Liability
Liabilities:
Total liabilities	1,169
Level 3
Liabilities:
Total liabilities	1,169
Level 3 | Convertible Preferred Stock Warrants Liability
Liabilities:
Total liabilities	$ 1,169

Fair Value Measurements - Sch_2

Fair Value Measurements - Schedule of Change in the Fair Value of the Warrant Liability (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Fair Value Disclosures [Abstract]
Beginning balance	$ 1,169	$ 213
Change in fair value of warrant liability	3,317	242
Conversion of preferred stock warrants to common stock warrants upon the closing of the IPO	$ (4,486)
Ending balance		$ 455

Inventories, Net - Additional I

Inventories, Net - Additional Information (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Inventory Disclosure [Abstract]
Inventory reserves	$ 318,000	$ 537,000

Inventories, Net - Schedule of

Inventories, Net - Schedule of Inventories, Net (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Inventory Disclosure [Abstract]
Raw materials	$ 1,817	$ 1,067
Work in process	911	640
Finished goods	2,892	2,246
Inventory, net	$ 5,620	$ 3,953

Property and Equipment. net - S

Property and Equipment. net - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 6,028	$ 4,610
Accumulated depreciation	(1,852)	(1,279)
Property and equipment, net	4,176	3,331
Manufacturing Equipment
Property Plant And Equipment [Line Items]
Property and equipment, gross	2,922	2,190
Leasehold Improvements
Property Plant And Equipment [Line Items]
Property and equipment, gross	1,012	932
Computer Software
Property Plant And Equipment [Line Items]
Property and equipment, gross	351	296
Furniture and Fixtures
Property Plant And Equipment [Line Items]
Property and equipment, gross	389	259
Computer Hardware
Property Plant And Equipment [Line Items]
Property and equipment, gross	711	527
Assets In Progress
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 643	$ 406

Property and Equipment. net - A

Property and Equipment. net - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Property Plant And Equipment [Line Items]
Depreciation expense			$ 573,000	$ 228,000
Capitalized implementation cost, net	$ 149,000		$ 149,000
Capitalized implementation cost, amortization method			The capitalized costs are amortized on a straight-line basis over the non-cancelable contract term of three years.
Capitalized implementation cost, amortization period	3 years		3 years
Capitalized implementation cost, current	$ 41,000		$ 41,000		$ 46,000
Capitalized implementation cost, noncurrent	54,000		54,000		$ 87,000
Operating Expense
Property Plant And Equipment [Line Items]
Depreciation expense	218,000	$ 95,000	418,000	185,000
Cost of Goods Sold
Property Plant And Equipment [Line Items]
Depreciation expense	81,000	$ 22,000	155,000	$ 43,000
Selling, General and Administrative Expenses
Property Plant And Equipment [Line Items]
Capitalized implementation cost, amortization	$ 16,000		$ 39,000

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details)	1 Months Ended	3 Months Ended		6 Months Ended
	Mar. 31, 2019Extension_Option	Jun. 30, 2020USD ($)	Jun. 30, 2019USD ($)	Jun. 30, 2020USD ($)	Jun. 30, 2019USD ($)
Lessee Lease Description [Line Items]
Operating lease, rent expense | $		$ 170,000	$ 51,000	$ 324,000	$ 101,000
Operating lease, expiration period				2024
Irvine, California
Lessee Lease Description [Line Items]
Operating lease, term of contract	5 years
Operating lease, expiration date	Sep. 30, 2024
Operating lease, number of extension options | Extension_Option	2
Option to extend, operating lease, term	5 years
Operating lease, Existence of option to extend	true
Operating lease, rent holiday concession period	1 month
Operating lease, description				The lease includes a one-month rent holiday concession and escalation clauses for increased rent over the lease term.

Commitments and Contingencies_2

Commitments and Contingencies - Schedule of Future Minimum Commitments (Details) $ in Thousands	Jun. 30, 2020USD ($)
Operating Lease Liabilities Payments Due [Abstract]
Remainder of 2020	$ 304
2021	628
2022	656
2023	707
2024	601
Future minimum commitments	$ 2,896

Concentrations - Additional Inf

Concentrations - Additional Information (Details)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2020CustomerVendor	Jun. 30, 2019CustomerVendor	Jun. 30, 2020CustomerVendor	Jun. 30, 2019CustomerVendor	Dec. 31, 2019CustomerVendor
Revenue | Customer Concentration Risk
Concentration Risk [Line Items]
Number of customers | Customer	0	0	0	0
Concentration risk	10.00%	10.00%	10.00%	10.00%
Accounts Receivable | Customer Concentration Risk
Concentration Risk [Line Items]
Number of customers | Customer			0		0
Concentration risk			10.00%		10.00%
Purchases | Supplier Concentration Risk
Concentration Risk [Line Items]
Concentration risk	10.00%	10.00%	10.00%	10.00%
Number of vendor | Vendor	0	0	0	0
Accounts Payable | Supplier Concentration Risk
Concentration Risk [Line Items]
Concentration risk			10.00%		10.00%
Number of vendor | Vendor			0		0

Related Party - Additional Info

Related Party - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
MRI The Hoffman Group
Related Party Transaction [Line Items]
Due to related parties	$ 0		$ 0		$ 0
Inceptus
Related Party Transaction [Line Items]
Reimbursement of expenses, milestone and administration fees					$ 139,000
Administration fee			18,000
Administrative fee payable upon completion of IPO	29,000		$ 29,000
Inceptus | Minimum
Related Party Transaction [Line Items]
Related party transaction, rate			1.00%
Royalty quarterly fee			$ 1,000
Inceptus | Maximum
Related Party Transaction [Line Items]
Related party transaction, rate			1.50%
Inceptus | Research and Development Expense
Related Party Transaction [Line Items]
Development expenses incurred	9,000	$ 3,000	$ 13,000	$ 6,000
Inceptus | Cost of Goods Sold
Related Party Transaction [Line Items]
Royalty expense	95,000		186,000
Recruiting Services | MRI The Hoffman Group
Related Party Transaction [Line Items]
Development expenses incurred	$ 170,000	$ 90,000	$ 249,000	$ 170,000

Debt - Schedule of Outstanding

Debt - Schedule of Outstanding Debt, Net of Deferred Financing Costs and Discounts (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
Total notes payables	$ 30,250	$ 20,150
Unamortized discount and debt issuance costs	(668)	(669)
Notes payable, net	29,582	19,481
Revolving Line of Credit
Debt Instrument [Line Items]
Total notes payables	5,000	5,000
Term Loan
Debt Instrument [Line Items]
Total notes payables	25,000	15,000
Final Payment Fee
Debt Instrument [Line Items]
Total notes payables	$ 250	$ 150

Debt - Additional Information (

Debt - Additional Information (Details)	1 Months Ended	6 Months Ended	12 Months Ended
	Dec. 31, 2019USD ($)Extension	Jun. 30, 2020USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2020USD ($)	Mar. 31, 2020USD ($)
SB Credit Facility
Debt Instrument [Line Items]
Credit facility	$ 40,000,000		$ 40,000,000
Minimum achievement of revenue to avail term loan	$ 60,000,000		60,000,000
Achievement of revenue to avail term loan period	2020-08
Facility fee paid		$ 50,000
Final payment fee percentage of funded term loan		1.00%
Final payment fee	$ 150,000	$ 250,000	150,000
Placement fee to broker			363,000
Legal and other fees			124,000
Financial covenants requirement minimum revenue	40,000,000		40,000,000
SB Credit Facility | Forecast
Debt Instrument [Line Items]
Financial covenants requirement minimum revenue				$ 60,000,000
SB Credit Facility | Revolving Line of Credit
Debt Instrument [Line Items]
Credit facility	$ 15,000,000		$ 15,000,000
Maturity date of credit facility	2022-12
Credit facility, frequency of periodic payment		monthly
Credit facility extended maturity period	2024-12
SB Credit Facility | Revolving Line of Credit | Maximum
Debt Instrument [Line Items]
Percentage of eligible accounts receivable to borrow, repay and re-borrow debt	80.00%		80.00%
Eligible accounts receivable to borrow, repay and re-borrow debt	$ 15,000,000		$ 15,000,000
SB Credit Facility | Revolving Line of Credit | Minimum
Debt Instrument [Line Items]
Annual interest rate of term loan	5.00%		5.00%
SB Credit Facility | Term Loan
Debt Instrument [Line Items]
Credit facility					$ 10,000,000
Maturity date of credit facility	2024-12
Credit facility, frequency of periodic payment		monthly
Interest only payments period	2021-12
Number of interest only extensions period | Extension	2
Debt instrument interest-only extensions period	6 months
SB Credit Facility | Term Loan | Prime Rate
Debt Instrument [Line Items]
Term loan variable interest rate	0.50%
SB Credit Facility | Term Loan | Maximum
Debt Instrument [Line Items]
Credit facility	$ 25,000,000		$ 25,000,000
SB Credit Facility | Term Loan | Minimum
Debt Instrument [Line Items]
Annual interest rate of term loan	5.50%		5.50%
SB Credit Facility | Term Loan Fully Funded on Closing Date
Debt Instrument [Line Items]
Credit facility	$ 15,000,000		$ 15,000,000
SB Credit Facility | Term Loan to be Available Through December 2020
Debt Instrument [Line Items]
Credit facility	10,000,000		10,000,000
SB Credit Facility | First Extension
Debt Instrument [Line Items]
Achievement of revenue milestones to available interest-only extensions period	$ 100,000,000		100,000,000
SB Credit Facility | Second Extension
Debt Instrument [Line Items]
Achievement of revenue to avail term loan period	2022-06
Achievement of revenue milestones to available interest-only extensions period	$ 113,000,000		$ 113,000,000
SB Credit Facility | First and Second Extension
Debt Instrument [Line Items]
Interest only payments period	2022-12
Term loan interest only-period	36 months
East West Bank | Term Loan
Debt Instrument [Line Items]
Repayments of debt	$ 10,000,000

Debt - Schedule of Maturities o

Debt - Schedule of Maturities of SB Credit Facility (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
Total future payments	$ 30,250	$ 20,150
Unamortized discount and debt issuance costs	(668)	(669)
Notes payable, net	29,582	$ 19,481
SB Credit Facility
Debt Instrument [Line Items]
2021	694
2022	8,333
2023	8,333
2024	12,890
Total future payments	30,250
Unamortized discount and debt issuance costs	(668)
Notes payable, net	$ 29,582

Debt - Schedule of Deferred Fin

Debt - Schedule of Deferred Financing Costs (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Debt Disclosure [Abstract]
Deferred financing costs	$ 798	$ 686
Accumulated amortization	(130)	(17)
Unamortized deferred financing costs	$ 668	$ 669

Redeemable Convertible Prefer_3

Redeemable Convertible Preferred Stock - Schedule of Redeemable Convertible Preferred Stock (Details) - USD ($) $ in Thousands	Jun. 30, 2020	May 31, 2020	Dec. 31, 2019
Temporary Equity [Line Items]
Shares Authorized			32,225,227
Shares Issued			31,968,570
Shares Outstanding	0	31,968,570	31,968,570
Net Carrying Value			$ 54,170
Liquidation Value	$ 0		$ 54,415
Series A Redeemable Convertible Preferred Stock
Temporary Equity [Line Items]
Shares Authorized			6,299,019
Shares Issued			6,221,977
Shares Outstanding			6,221,977
Net Carrying Value			$ 8,777
Liquidation Value			$ 8,885
Series B Redeemable Convertible Preferred Stock
Temporary Equity [Line Items]
Shares Authorized			11,270,319
Shares Issued			11,090,726
Shares Outstanding			11,090,726
Net Carrying Value			$ 18,474
Liquidation Value			$ 18,530
Series C Redeemable Convertible Preferred Stock
Temporary Equity [Line Items]
Shares Authorized			14,655,889
Shares Issued			14,655,867
Shares Outstanding			14,655,867
Net Carrying Value			$ 26,919
Liquidation Value			$ 27,000

Redeemable Convertible Prefer_4

Redeemable Convertible Preferred Stock - Additional Information (Details) - USD ($) $ in Millions	1 Months Ended
	May 31, 2020	Jun. 30, 2020	Dec. 31, 2019
Temporary Equity Disclosure [Abstract]
Redeemable convertible preferred stock, shares outstanding	31,968,570	0	31,968,570
Preferred stock converted into common stock	31,968,570
Reclassification of redeemable convertible preferred stock to common stock and additional paid in capital	$ 54.2

Stockholder's Equity- Additiona

Stockholder's Equity- Additional Information (Details) - $ / shares	Jun. 30, 2020	May 31, 2020	May 27, 2020	Dec. 31, 2019
Class Of Stock [Line Items]
Authorized capital	310,000,000			81,244,834
Common stock, shares authorized	300,000,000			49,019,607
Common stock, par value	$ 0.001			$ 0.001
Redeemable convertible preferred stock, shares authorized				32,225,227
Redeemable convertible preferred stock, par value	$ 0.001			$ 0.001
Preferred stock, shares authorized	10,000,000			10,000,000
Preferred stock, Par value	$ 0.001			$ 0.001
Preferred stock, shares outstanding	0			0
Class of warrant exercised for cash	77,030
Number of common stock shares issued upon exercise of preferred stock warrants	74,723
Redeemable Convertible Preferred Stock Warrants
Class Of Stock [Line Items]
Converted into warrants to purchase common stock		256,588	256,588
Common Stock Warrants
Class Of Stock [Line Items]
Class of warrant exercised for cash	27,810
Series A Preferred Stock
Class Of Stock [Line Items]
Redeemable convertible preferred stock, shares authorized				6,299,019
Series B Preferred Stock
Class Of Stock [Line Items]
Redeemable convertible preferred stock, shares authorized				11,270,319
Series C Preferred Stock
Class Of Stock [Line Items]
Redeemable convertible preferred stock, shares authorized				14,655,889

Stockholder's Equity - Schedule

Stockholder's Equity - Schedule of Warrants Issued and Outstanding (Details) - $ / shares	Jun. 30, 2020	Dec. 31, 2019
Class Of Warrant Or Right [Line Items]
Number of warrants outstanding	179,558	284,398
Common Stock Warrants
Class Of Warrant Or Right [Line Items]
Number of warrants outstanding	179,558	27,810
Warrants Outstanding Exercise Price	$ 1.67	$ 0.14
Warrants Outstanding Expiration		Oct. 19, 2025
Common Stock Warrants | Minimum
Class Of Warrant Or Right [Line Items]
Warrants Outstanding Expiration	Apr. 28, 2026
Common Stock Warrants | Maximum
Class Of Warrant Or Right [Line Items]
Warrants Outstanding Expiration	Mar. 30, 2027
Series A Preferred Stock Warrants
Class Of Warrant Or Right [Line Items]
Number of warrants outstanding		77,030
Warrants Outstanding Exercise Price		$ 1.43
Warrants Outstanding Expiration		Dec. 10, 2021
Series B Preferred Stock Warrants
Class Of Warrant Or Right [Line Items]
Number of warrants outstanding		179,558
Warrants Outstanding Exercise Price		$ 1.67
Series B Preferred Stock Warrants | Minimum
Class Of Warrant Or Right [Line Items]
Warrants Outstanding Expiration		Apr. 28, 2026
Series B Preferred Stock Warrants | Maximum
Class Of Warrant Or Right [Line Items]
Warrants Outstanding Expiration		Mar. 30, 2027
Redeemable Convertible Preferred Stock Warrants
Class Of Warrant Or Right [Line Items]
Number of warrants outstanding		256,588

Stockholder's Equity - Schedu_2

Stockholder's Equity - Schedule of Fair Value of Preferred Warrants Determined Using Black Scholes Option Pricing Model (Details)	May 21, 2020$ / shares	Dec. 31, 2019$ / shares
Series A
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Preferred stock fair value (per share)	$ 19	$ 5.88
Series B
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Preferred stock fair value (per share)	$ 19	$ 5.94
Expected Volatility | Series A
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair value measurement input	51.10	41.40
Expected Volatility | Series B
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair value measurement input	50	39.80
Dividend Yield | Series A
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair value measurement input	0	0
Dividend Yield | Series B
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair value measurement input	0	0
Risk Free Interest Rates | Series A
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair value measurement input	0.17	1.58
Risk Free Interest Rates | Series B
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair value measurement input	0.53	1.83
Expected Remaining Term | Series A
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Expected remaining term in years	1 year 6 months 18 days	1 year 11 months 12 days
Expected Remaining Term | Series B | Minimum
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Expected remaining term in years	5 years 11 months 8 days	6 years 3 months 29 days
Expected Remaining Term | Series B | Maximum
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Expected remaining term in years	6 years 10 months 9 days	7 years 3 months

Equity Incentive Plan - Additio

Equity Incentive Plan - Additional Information (Details) - USD ($)	1 Months Ended			3 Months Ended		5 Months Ended	6 Months Ended
	May 31, 2020	Mar. 31, 2020	Mar. 31, 2019	Jun. 30, 2020	Jun. 30, 2019	May 21, 2020	Jun. 30, 2020	Jun. 30, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense				$ 505,000	$ 99,000		$ 1,000,000	$ 190,000
Compensation costs related to all non-vested awards to be recognized in future				$ 7,967,000			$ 7,967,000
Non vested stock awards, expected weighted average period							3 years 4 months 24 days
Restricted Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Award vesting period			4 years
Stock-based compensation expense						$ 0
Restricted Stock Units | IPO
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense							$ 159,000
2020 Incentive Award Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares of common stock reserved for future issuance		3,468,048
Percentage of annual increase in shares reserved for issuance on capital stock outstanding at year end		3.00%
Number of shares available for issuance				3,658,683			3,658,683
Number of shares granted							104,538
2020 Incentive Award Plan | Restricted Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Award vesting period							4 years
Share-based compensation vesting rights, terms							The RSUs generally vest over a four-year period with straight-line vesting and a 25% one year cliff or over a three year period in equal amounts on a quarterly basis, provided the employee remains continuously employed with the Company.
2020 Incentive Award Plan | Restricted Stock Units | Share Based Compensation Award Tranche One
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Cliff vesting, percentage							25.00%
2020 Incentive Award Plan | Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Term of award		10 years
2011 Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares available for issuance				269,268			269,268
2011 Equity Incentive Plan | Restricted Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares granted			2,867,326
2020 Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares of common stock reserved for future issuance	990,870
First offering start date	Aug. 1, 2020
First offering end date	Jan. 31, 2021
Percentage of purchase price on fair market value of common stock	85.00%

Equity Incentive Plan - Summary

Equity Incentive Plan - Summary of Stock Option Activity (Details) - 2011 Equity Incentive Plan $ / shares in Units, $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2020USD ($)$ / sharesshares	Dec. 31, 2019USD ($)$ / sharesshares
Number of Awards
Number of Awards, Outstanding, Beginning balance | shares	4,082,302
Number of Awards, Granted | shares	305,494
Number of Awards, Exercised | shares	(135,263)
Number of Awards, Cancelled | shares	(98,380)
Number of Awards, Outstanding, Ending balance | shares	4,154,153	4,082,302
Number of Awards, Vested and exercisable | shares	1,508,051
Number of Awards, Vested and expected to vest | shares	4,154,153
Weighted Average Exercise Price
Weighted Average Exercise Price, Outstanding, Beginning balance	$ 0.90
Weighted Average Exercise Price, Granted	7.47
Weighted Average Exercise Price, Exercised	0.50
Weighted Average Exercise Price, Cancelled	8.50
Weighted Average Exercise Price, Outstanding, Ending balance	1.22	$ 0.90
Weighted Average Exercise Price, Vested and exercisable	0.54
Weighted Average Exercise Price, Vested and expected to vest	1.22
Weighted Average Fair Value
Weighted Average Fair Value, Outstanding, Beginning balance	0.74
Weighted Average Fair Value, Granted	3.73
Weighted Average Fair Value, Exercised	0.38
Weighted Average Fair Value, Cancelled	3.63
Weighted Average Fair Value, Outstanding, Ending balance	0.90	$ 0.74
Weighted Average Fair Value, Vested and exercisable	0.46
Weighted Average Fair Value, Vested and expected to vest	$ 0.90
Weighted Average Remaining Contractual Life (in years)
Weighted Average Remaining Contractual Life (in years), Outstanding	8 years 4 months 13 days	8 years 9 months 3 days
Weighted Average Remaining Contractual Life (in years), Vested and exercisable	7 years 10 months 13 days
Weighted Average Remaining Contractual Life (in years), Vested and expected to vest	8 years 4 months 13 days
Intrinsic Value
Intrinsic Value, Outstanding, Beginning balance | $	$ 22,667
Intrinsic Value, Exercised | $	3,381
Intrinsic Value, Cancelled | $	1,007
Intrinsic Value, Outstanding, Ending balance | $	196,160	$ 22,667
Intrinsic Value, Vested and exercisable | $	72,241
Intrinsic Value, Vested and expected to vest | $	$ 196,160

Equity Incentive Plan - Schedul

Equity Incentive Plan - Schedule of Estimated Fair Value of Option Grant on Date of Grant (Details) - $ / shares	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected volatility	40.60%
Expected volatility, minimum		82.10%
Expected volatility, maximum		93.40%
Weighted-average volatility	40.60%	92.07%
Dividend yield	0.00%	0.00%
Risk free interest rates, minimum	1.46%	1.85%
Risk free interest rates, maximum	1.68%	2.44%
Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock fair value (per share)	$ 7.88	$ 0.59
Expected remaining term in years	5 years 10 months 24 days	5 years 11 months 19 days
Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock fair value (per share)	$ 9.05	$ 1.01
Expected remaining term in years	6 years 25 days	6 years 21 days

Equity Incentive Plan - Summa_2

Equity Incentive Plan - Summary of RSU Activity (Details) - 2020 Incentive Award Plan $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2020USD ($)$ / sharesshares
Number of Awards
Number of shares granted | shares	104,538
Number of Awards, Outstanding, Ending balance | shares	104,538
Number of Awards, Vested and expected to vest | shares	104,538
Weighted Average Fair Value
Weighted Average Fair Value, Granted | $ / shares	$ 49.25
Weighted Average Fair Value, Outstanding, Ending balance | $ / shares	49.25
Weighted Average Fair Value, Vested and expected to vest | $ / shares	$ 49.25
Intrinsic Value
Intrinsic Value, Granted | $	$ 5,128
Intrinsic Value, Outstanding, Ending balance | $	50,638
Intrinsic Value, Vested and expected to vest | $	$ 50,638

Equity Incentive Plan - Sched_2

Equity Incentive Plan - Schedule of Total Compensation Cost for All Share-Based Payment Arrangements Recognized (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total compensation cost	$ 505	$ 99	$ 1,000	$ 190
Cost of Goods Sold
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total compensation cost	42	9	72	12
Research and Development Expense
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total compensation cost	77	21	124	40
Selling, General and Administrative
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total compensation cost	$ 386	$ 69	$ 804	$ 138

Income Taxes - Schedule of Prov

Income Taxes - Schedule of Provision (Benefit) for Income Taxes (Details) - USD ($)	3 Months Ended				6 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2020	Jun. 30, 2019
Income Tax Disclosure [Abstract]
Income (loss) before taxes	$ (3,804,000)		$ (965,000)		$ 308,000	$ (1,913,000)
Income tax provision (benefit)	0		0		0	0
Net income (loss) and comprehensive income (loss)	$ (3,804,000)	$ 4,112,000	$ (965,000)	$ (948,000)	$ 308,000	$ (1,913,000)
Income tax provision (benefit) as a percentage of income taxes	0.00%		0.00%		0.00%	0.00%

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Income Tax Disclosure [Abstract]
Income tax provision (benefit)	$ 0	$ 0	$ 0	$ 0
Interest or penalties related to uncertain tax positions			$ 0
Significant change in unrecognized tax position, description			It is not expected that there will be a significant change in uncertain tax position in the next 12 months.
Income tax examination, description			In the normal course of business, the Company is subject to examination by tax authorities. As of the date of the financial statements, there are no tax examinations in progress. The statute of limitations for tax years ended after December 31, 2015 and December 31, 2016 are open for state and federal tax purposes, respectively.

Retirement Plan - Additional In

Retirement Plan - Additional Information (Details)	6 Months Ended
	Jun. 30, 2020
Compensation And Retirement Disclosure [Abstract]
Company matching contributions	0.00%

Net Loss Per Share - Schedule o

Net Loss Per Share - Schedule of Outstanding Potentially Dilutive Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2019
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	25,813,190	39,636,184	39,636,184
Convertible Preferred Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	18,267,754	31,968,570	31,968,570
Common Stock Options
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	4,154,153	3,949,631	3,949,631
RSUs
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	2,971,864	2,867,326	2,867,326
Restricted Stock Subject to Future Vesting
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	239,861	566,259	566,259
Convertible Preferred Stock Warrants
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share		256,588	256,588
Common Stock Warrants
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	179,558	27,810	27,810